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1. INTRODUCTION 
Vascular surgery is considered an intermediate-to-high-risk surgery as the risk 
for 30-day cardiovascular mortality or myocardial infarction is estimated to be 
greater than 5% in peripheral revascularisation surgery and open aortic aneurysm 
repair and 1–5% in carotid endarterectomy (Boersma et al. 2005). Additionally, 
vascular surgery increases the risk for renal insufficiency as postoperative acute 
kidney injury (AKI) has been found to occur in 12.7–49% of patients undergoing 
vascular surgery (Adalbert et al. 2013; Huber et al. 2016). Patients undergoing 
vascular surgery usually have multiple comorbidities resulting from systemic 
atherosclerosis. Coexisting diseases combined with major tissue trauma increase 
the peri-operative risk, mainly in terms of cardiovascular events. Moreover, during 
revascularisation surgery, ischaemia-reperfusion (I/R) injury and rhabdomyolysis 
are inevitable, which increases the risk for kidney injury. Consequently, there 
arises the need for an effective risk reduction strategy. 
The protective effects of short nonlethal episodes of ischaemia on dog heart 
were first described decades ago (Murry et al. 1986) and this phenomenon was 
called ischaemic preconditioning (IPC). Later, the cardioprotective effects of 
ischaemic precondition to distant tissues were described in terms of the discovery 
that ischaemia episodes in one vascular bed offers protection also to another 
vascular bed (Przyklenk et al. 1993), which was the first published evidence of 
remote ischaemic preconditioning (RIPC). The effect of IPC on different organs 
has been widely studied in animals and since 2006 also in humans (Cheung et al. 
2006). The exact mechanisms of ischaemic conditioning are not known, but 
during the last decade multiple pathways and biochemical markers involved in 
achieving the effect of ischaemic conditioning have been discovered. Most 
generally, humoral and neural pathways are believed to be involved (Aimo et al. 
2015). Nevertheless, there are still uncertainties about the conditions under which 
RIPC has a protective effect and about whether it should be performed routinely. 
The metabolism of the human body and the heterogeneity between individuals 
may also alter the effect of RIPC. Metabolomic profiling of RIPC, i.e. studying 
the systemic effect of RIPC on low-molecular weight metabolites in humans may 
therefore help to understand better the mechanisms and potential targets of 
ischaemic conditioning and to find out what is essential for achieving the protective 
effects of RIPC. Consequently, it is possible to select eligible patients for RIPC.  
The present research was undertaken to assess the effect of RIPC on arterial 
stiffness (i.e. hypertension mediated organ damage), on heart and kidneys and on 
acylcarnitines’ metabolism in patients undergoing vascular surgery, as well as to 
gain a better understanding of the mechanisms of RIPC and of the factors ensuring 
its protective effects.  
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2. REVIEW OF THE LITERATURE 
2.1. Protective effects of remote ischaemic preconditioning 
2.1.1. Ischaemia-reperfusion injury 
In the case of prolonged ischaemia, accumulation of lactic acid and depletion of 
ATP occurs, which leads to failure of Na+–K+ and Ca2+ pumps. This results in an 
intracellular increase of Ca2+ and Na+ and a decrease of K+, which can lead to cell 
swelling decline in cellular integrity. Even though reperfusion of the ischaemic 
tissue is necessary to prevent irreversible ischaemic damage, reperfusion itself 
paradoxically also promotes further damage and dysfunction, which is called 
reperfusion injury. In the event of restoring blood flow to ischaemic tissue, 
oxygen is provided along with reactive oxygen species (ROS). In ischaemic 
tissues, there is a lack of antioxidative agents, which causes oxidative stress. This 
leads to inflammatory response, endothelial dysfunction, and to DNA and other 
damage of cellular structure. The state of reperfusion damage may persist for 
several days (Wu et al. 2018). The damage is not only local; there has been found 
to occur also systemic stress response (Karg et al. 1997; García-de-la-Asunción 
et al. 2012). It has been established that reperfusion causes microvascular 
dysfunction both in local and distant tissues (Carden and Granger 2000) and 
restoration of the blood flow in lower limbs leads to kidney, lung and liver 
damage (Yassin et al. 2002). The target of RIPC is a situation where I/R injury is 
present or there is a risk for it. In addition to preconditioning, ischaemic 
conditioning has the potential for organ protection, being applied not only prior 
to ischaemia, but also after ischaemia and before reperfusion (remote ischaemic 
periconditioning, RIPerC) and similarly during reperfusion (remote ischaemic 
postconditioning, RIPostC).  
 
 
2.1.2. Study targets 
The effect of RIPC on heart has been most intensively studied in heart-related 
procedures like cardiac surgery and percutaneous transluminal coronary angio-
plasty (PTCA), where I/R injury is direct and often inevitable (Piper et al. 1998). 
However, during cardiac surgery, secondary damage to the kidneys (Wang and 
Bellomo 2017) or primary damage due to contrast dye in the case of PTCA 
(Geenen et al. 2013) may occur and the nephroprotective effects of RIPC are of 
great interest. Also, there is a risk for acute kidney and heart damage in other 
major surgeries such as vascular surgery (Flu et al. 2010; Hobson et al. 2018). 
Nowadays, the range of organs studied for the protective effects of RIPC is wide. 
Increasingly more studies focus on the effects of RIPC on lungs (Weber et al. 
2018), liver (Ruan et al. 2016; Koh et al. 2019), brain (Lv et al. 2020) and 
intestines (Hummitzsch et al. 2019) – everywhere where I/R damage plays an 
important role. One of the new directions is transplantation surgery involving 
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liver (Jung et al. 2020), heart (Wang et al. 2019a) and kidney (Veighey et al. 
2019). In addition to elective procedures, studies on RIPC have been shifted to 
emergency situations such as myocardial infarction (Liu et al. 2016) and stroke 
(Che et al. 2019). Possibly, interest in other acute ischaemic situations such as 
mesenteric ischaemia or pulmonary embolism might be increasing. Also, the 
effect of chronic ischaemic conditioning has been studied (Tong et al. 2019). 
Nevertheless, the number of studies focusing on the effect of RIPC in vascular 
surgery has been limited and the studies tend to be rather small or involving 
important confounders. 
 
 
2.1.3. Arteries and cardiovascular diseases  
2.1.3.1. Endothelial function and arterial stiffness 
Arterial stiffening is considered a characteristic of hypertension-mediated organ 
damage in the latest version of the ESC/ESH guidelines for arterial hypertension 
(Williams et al. 2018). Three studies have focused on the effects of RIPC on 
arterial stiffness parameters. The first study (Zagidullin et al. 2016) found that 
RIPC reduced MAP, augmentation index (AIx), and systolic blood pressure in 
patients with stable angina pectoris and linked the effect to improvement in 
endothelial function. Another study (Kuusik et al. 2019) demonstrated that RIPC 
reduced significantly AIx and blood pressure in patients undergoing angiographic 
procedures on the lower limb. However, the last study (Müller et al. 2019) did 
not find any effect of RIPC on arterial stiffness, blood pressure or heart rate in 
young healthy adults. This can be explained by the assumption that the effect of 
RIPC may be revealed only when damage, in this case, arterial stiffening, is 
present, but young healthy adults presumably have normal arteries.  
Multiple factors have been found to contribute to the mechanisms of RIPC, 
with some being directly connected to endothelial function. It was recently shown 
that RIPC reduces vasoconstriction induced by acetylcholine in patients under-
going elective coronary angiography (Corcoran et al. 2018). The positive effect 
of RIPC on vasodilatation in the microvasculature has also been described (Lang 
et al. 2019). In addition, several studies have demonstrated the role of nitric oxide 
(NO), an endothelium-derived relaxing factor, in the mechanisms of RIPC in non-
clinical settings (Chen et al. 2005; Kang et al. 2013). Moreover, in a systematic 
review, it was emphasized that RIPC promotes endothelial function and has a 
long-term effect on lowering systolic and diastolic pressures and MAP (Epps et 
al. 2016). Additionally, the beneficial effects of RIPC on arterial compliance can 
be linked to increased numbers of endothelial progenitor cells and elevated 
expression of vascular endothelial growth factor (Liu et al. 2013), but also to 
activation of the parasympathetic nervous system (Donato et al. 2016). 
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2.1.3.2. Peripheral artery disease and cerebrovascular disease. 
Although intermittent claudication and other clinical forms of peripheral artery 
diseases (PAD) can be viewed as chronic preconditioning, an additional effect of 
RIPC has deserved attention. It has been found that four weeks of daily RIPC 
prolongs the walking distance and relieves claudication symptoms in patients 
with intermittent claudication (Balin and Kıvrak 2019). Additionally, RIPC 
demonstrated a positive effect on the initial claudication distance (Saes et al. 
2013) and ankle-brachial index in patients with PAD (Shahvazian et al. 2017). 
However, when performed only before treadmill walking test, RIPC has shown 
contradictory results as Delagarde et al. did not find any effect of it on 
claudication (Delagarde et al. 2015). 
More studies have been published about the effect of RIPC in cerebrovascular 
diseases. It has been found that RIPC offers neuroprotection in reducing infarction 
size and improving neurological recovery after brain injury following hypothermic 
circulatory arrest (Jensen et al. 2011) and ischaemic stroke (Ren et al. 2008; Du 
et al. 2020) in animals. In addition, RIPC enhances collateral circulation (Zhang 
et al. 2019). Protection from ischaemia and cell membrane preservation up to 2 
days following RIPC has been described in patients with aneurysmal sub-
arachnoid haemorrhage (Gonzalez et al. 2013). Furthermore, daily RIPC has been 
found to reduce the incidence of recurrent stroke from 26.9% to 7.9% during 
300 days, to increase cerebral perfusion in patients with symptomatic athero-
sclerotic stenosis of the intracranial arteries (Meng et al. 2012) and to improve 
neurological outcome after stroke (England et al. 2017). Also, in the case of 
carotid endarterectomy, RIPC has been shown to reduce the size of brain lesions 
(Zhao et al. 2017).  
 
 
2.1.3.3. Heart diseases 
The best studied organ regarding the effect of RIPC is possibly the heart and 
relevant studies tend to be larger and to have more statistical power than those 
addressing other organs. There are multiple positive results from animal studies 
and from the proof of concept studies. In multiple trials on animals, RIPC has 
reduced the size of infarct (Gho et al. 1996; Tang et al. 1999; Schoemaker and 
van Heijningen 2000; Liem et al. 2002; Weinbrenner et al. 2002; Konstantinov et 
al. 2005; Wolfrum et al. 2005; Zhang et al. 2006; Dong et al. 2018; Lieder et al. 
2018; Bunte et al. 2019). However, there are other potential positive effects of 
RIPC on the heart. For example, RIPC has been found to reduce reperfusion-
related arrhythmias (Dow et al. 2012; Jang et al. 2017), but also atrial fibrillation 
in non-ischaemic conditions (Han et al. 2016). Also, RIPC has been found to be 
useful in heart transplantation, as it reduces I/R injury in the brain-dead donor 
heart (Konstantinov et al. 2005). The effect of RIPC in ischaemic heart diseases 
is quite well studied. Still, besides consistent positive results from animal studies, 
those from clinical studies are somewhat contradictory. Although there are some 
larger RCTs that have described the cardioprotective effect of RIPC in patients 
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under elective percutaneous coronary intervention (PCI) (Bøtker et al. 2010; 
Pryds et al. 2016), three largest trials in patients undergoing coronary artery 
bypass surgery found no clinically relevant cardioprotection by RIPC (Hong et 
al. 2014; Hausenloy et al. 2015; Meybohm et al. 2015). The effect of RIPerC and 
RIPostC has been more thoroughly studied in patients with ST-segment elevation 
myocardial infarction (STEMI). Attenuation of cardiac damage has been 
described in patients undergoing primary PCI (Crimi et al. 2013; Cao et al. 2018) 
and higher rate of resolution of ST-segment elevation has been described in the 
case of thrombolysis (Ghaffari et al. 2018). Moreover, RIPerC has appeared to be 
feasible and safe in patients with STEMI and has not been found to prolong 
bedside time. Patients with STEMI have even been suggested as an ideal group 
for RIPC utilization (Martin-Gill et al. 2016).  
The threat of cardiac damage is prevalent also in non-cardiac surgeries, espe-
cially in high risk procedures such as vascular surgery (Flu et al. 2010). RIPC has 
been shown to reduce the leakage of troponin and the incidence of myocardial 
infarction in patients undergoing open abdominal aortic aneurysm (AAA) repair 
surgery (Ali et al. 2007). In contrast, neither of the more recent two larger trials 
reported the benefit from RIPC to patients undergoing open AAA repair, carotid 
endarterectomy or surgical lower limb revascularisation (Healy et al. 2015; 
Garcia et al. 2016). Still, in a larger trial with patients undergoing emergency hip 
fracture surgery, RIPC was found to reduce the risk of myocardial injury and 
infarction (Ekeloef et al. 2019). Summing up, although many studies have dealt 
with the cardioprotective effects of RIPC, it needs to be clarified who exactly will 
benefit from this procedure in terms of cardioprotection.  
 
 
2.1.4. Kidney injury 
One of the organs of interest for application of RIPC is the kidney due to its 
sensitivity to ischaemic injury. Ischaemia can occur in various surgeries; e.g. AKI 
has been found to affect 12.7% of patients undergoing lower limb revascu-
larisation surgery (Adalbert et al. 2013) and even up to 30% patients requiring 
cardiac surgery (Hobson et al. 2009). In addition, contrast-induced nephropathy 
(CIN) is caused by medullary ischaemia and is a threat to many patients who need 
an exam with contrast medium, e.g. PCI. According to a meta-analysis, RIPC was 
found to reduce AKI in patients requiring cardiac surgery (Zhang et al. 2016; 
Zhou et al. 2017) and in those undergoing PCI (Wang et al. 2017b). In a large 
meta-analysis including studies on patients undergoing cardiac and vascular 
surgery, AKI was reduced by RIPC, but the statistical heterogeneity of these 
studies was high (Li et al. 2017). The nephroprotective effects of RIPC have also 
been studied in patients undergoing non-cardiac vascular surgery. Although early 
studies reported a nephroprotective effect (Ali et al. 2007; Walsh et al. 2009), the 
last 3 large studies report no benefit (Healy et al. 2015; Garcia et al. 2016; Thomas 
et al. 2016). Also, there is an increasing need for methods to reduce CIN and 
RIPC has been even more studied in the light of this response. In a recent meta-
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analysis, it was concluded that RIPC is an effective procedure to reduce the risk 
of CIN in patients undergoing PCI or coronary angiography, who have moderate-
to-high risk for developing CIN (Pranata et al. 2020). However, it was found 
earlier that RIPC did not have any additional effect in preventing development of 
CIN (Ghaemian et al. 2018). Regarding a more recently emerged area of interest, 
i.e. transplantation medicine, RIPC improved long-term renal function after living-
donor kidney transplantation, when administered before the induction of anaes-
thesia (Veighey et al. 2019). 
 
 
2.1.5. The most effective protocol for RIPC and its timing 
No optimal RIPC protocol has been established to this date. Usually, a protocol 
consisting of 3 or 4 cycles of 5-minute ischaemia is used. However, application of 
such a protocol has led to both positive and negative outcomes. Some studies with 
longer or shorter episodes or with a different number of cycles have had positive 
outcomes. Most meta-analyses have reached the conclusion that an optimal RIPC 
protocol is yet to be established. The first animal study (Murry et al. 1986) and a 
human study (Cheung et al. 2006), which assessed the effect of ischaemic pre-
conditioning used a protocol of 5 min in a quadruple. It has been concluded that 
4 to 6 RIPC cycles provided significant cardioprotection and that one- and two-
hind-limb preconditioning are equally protective (Johnsen et al. 2016). In a meta-
analysis, it was established that an ischaemia episode should last at least 5 minutes, 
but no conclusions were drawn regarding the number of cycles (Pei et al. 2014). 
In 1993, it was reported that the effect of RIPC can be observed up to 24 hours 
after the preconditioning stimulus (Kuzuya et al. 1993). Two “windows” of the 
effect of preconditioning have been described: the first lasting a few hours after 
conditioning and the second appearing 24 hours after conditioning (Louko-
georgakis et al. 2005). The second “window” has been reported to last 24 to 72 
hours after the preconditioning stimulus (Baxter et al. 1997). Daily ischaemic 
preconditioning for a longer period has also been studied and the protocols are 
similar to ischaemic conditioning with one or two sessions (Epps et al. 2016; 
Maxwell et al. 2019). No complications of noninvasive ischemic conditioning 
have been reported and it is well-tolerated by patients (Anttila et al. 2016; Guo et 
al. 2019).  
 
 
  
 
16 
2.2. Mechanisms of RIPC  
2.2.1. Humoral factors of RIPC 
2.2.1.1. Nitric oxide (NO) 
Ischaemic conditioning performed directly or remotely has been described to 
induce vasodilatation (Enko et al. 2011) and to preserve endothelial function 
(Kharbanda et al. 2001, 2002; Loukogeorgakis et al. 2005). The role of NO, the 
signalling molecule, which is iconic of endothelial function, has been studied in 
the protective mechanisms of RIPC in different organs. RIPC was found to 
increase the levels of intracoronary NO and was associated with cardiac salvage 
(Arroyo-Martínez et al. 2016). Also, RIPC was reported to reduce liver (Abu-
Amara et al. 2011; Duan et al. 2017), brain (Vlasov et al. 2005) and kidney (Jung 
et al. 2019) I/R injury by affecting the eNOS-NO pathway.  
 
 
2.2.1.2. Anti-apoptotic and anti-inflammatory effects 
I/R injury leads to cell death: during ischaemia, both necrosis and apoptosis 
occur, but reperfusion enhances apoptosis even more (Eefting et al. 2004). 
Ischemic conditioning has demonstrated anti-apoptotic effects by inhibition of 
endogenous mitochondrial pathways (Lv et al. 2020) and reducing apoptosis by 
activation of phosphoinositide 3-kinase (PI-3)/Akt signalling (Li et al. 2011). 
Inflammation is the major response of the human body to tissue damage and has 
an important role in I/R injury (Chen et al. 2017). As a protective mechanism, it 
often helps to eliminate the cause of injury, yet it has harmful effects itself. To 
avoid its unnecessary damage, inflammatory response can be modulated (Yang 
et al. 2018; Zapata-Chavira et al. 2019). 
One of the effects of RIPC is inducing a decrease in inflammation mediators, 
among which hypoxia inducible factor-1α (HIF-1α) plays a key role in this 
context (Yang et al. 2018). Ischaemic conditioning has also been found to reduce 
the levels of proinflammatory cytokines (e.g. IL-1β, IL-6, TNF-α) and to increase 
the levels of anti-inflammatory cytokines IL-10 (Kim et al. 2014; Xia et al. 2019) 
and hence to reduce neutrophil activation. Suppression of inflammation leads to 
suppression of reactive oxygen species (ROS), which ameliorates oxidative 
status. In addition, the cardioprotective effects of RIPC have also been linked to 
modulation of autophagy (Billah et al. 2020). The organ protective effect of RIPC 
has been associated with both inducing (Rohailla et al. 2014; Wang et al. 2014) 
and inhibiting (Gurusamy et al. 2009; Huang et al. 2010) autophagy. Inhibition 
of the proapoptotic- and inflammatory pathways has been associated with 
activation of the JAK2/STAT3 pathway (Cheng et al. 2014). 
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2.2.1.3. Anti-oxidative stress 
Along with inflammatory response to tissue damage caused by medical pro-
cedures and diseases, oxidative stress (OxS) is induced, which enhances total 
tissue damage. There is evidence that the protective effects of RIPC are mediated 
through opposing OxS (Arvola et al. 2016; Motomura et al. 2017). RIPC has been 
shown to have antioxidative effects in renal I/R injury, which is linked to 
preventing damage to the kidneys (Hussein et al. 2016; Dong et al. 2018; Hu et 
al. 2018). In patients with STEMI undergoing PCI, RIPostC has been found to 
increase the levels of powerful anti-oxidants such as glutathione peroxidase and 
superoxide dismutase, as well as to increase total antioxidant capacity (Lotfollahi 
et al. 2016). This probably plays an important role in the salvage of the myo-
cardium.  
 
 
2.2.1.4. Mitochondria 
I/R injury is associated with impairment of mitochondrial function. In addition, 
inflammatory response promotes catabolic pathways, which increases the load on 
mitochondria as they occupy a principal position in energy metabolism. Cardio-
protection by RIPC has been shown to occur along with improved mitochondrial 
function (Gedik et al. 2017; Paez et al. 2019) in animals. Also, evidence suggests 
that preservation of mitochondrial respiration is achieved by RIPC in humans 
(Slagsvold et al. 2014) and that cardioprotection is related to mitochondrial 
salvage (Kleinbongard et al. 2018).  
 
 
2.2.1.5. Platelets 
Platelets have major a role in thrombosis, haemostasis, atherogenesis and inflam-
mation, and have also been found to be important players in various types of 
cardiovascular diseases (Malchow et al. 2017). Platelets also participate in the 
protective mechanism of IPC. Specifically, a crucial role has been assigned to 
serotonin, which is released by activated platelets and activates the VEGF/IL-
10/MMP8 pathway (Oberkofler et al. 2014). Also, platelet-derived microparticles 
have been found to mediate the cardioprotective effects of RIPC (Ma et al. 2015). 
The importance of platelets has been demonstrated by the finding that thrombo-
cytopenia and the lack of platelet serotonin abolishes the protective effect of 
RIPC against hepatic I/R injury (Oberkofler et al. 2014). On the other hand, RIPC 
had no effect on hemostasis or fibrinolysis, or on the occurrence of thromboem-
bolic complications in cancer patients who underwent surgery (Krag et al. 2019). 
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2.2.1.6. Transcription – JAK-STAT pathway 
The JAK-STAT signalling pathway is involved in many processes in the human 
body, e.g. cell death and inflammation. Also, it has been found to be activated in 
both the first and the second windows of RIPC (Hattori et al. 2001; Xuan et al. 
2001). Among the STAT proteins, the one essential for achieving the effect of 
RIPC is STAT3 (Oshima et al. 2005; Butler et al. 2006) and STAT5 (Heusch et 
al. 2012; Bibli et al. 2014). STAT3 has been found to have a key role in apoptosis 
(Yuan et al. 2004). In the second window, the main effect of activating STAT3 is 
most probably reduction in cell apoptosis (Bolli 2000). STAT5 is believed to 
induce cardioprotection in the second window by promoting angiogenesis, 
releasing survival signals and inhibiting apoptosis (Chen et al. 2018). However, 
the effect in the first window is not so clear. It has been suggested that the effect 
in the first window may be evoked by posttranslational protein modification, 
activation of supplementary intracellular kinases (Hattori et al. 2001), upregu-
lation of superoxide dismutase (S et al. 2001) and upregulation of inducible NO 
synthase (Bolli 2000). RIPC has also been found to reduce the activity of Nf-κb, 
and hence reduces the inflammatory response by reducing the transcription of 
major pro-inflammatory cytokines (Cheng et al. 2014). 
 
 
2.2.2. Neural pathways and RIPC 
2.2.2.1. Sympathetic and parasympathetic nervous systems 
The autonomic nervous system consists of sympathetic and parasympathetic 
divisions that function in opposition to each other controlling all autonomic 
functions, such as respirations, cardiac and vasomotor actions. The sympathetic 
division is involved in actions requiring quick response, the so called „fight or 
flight“ response, while the parasympathetic division acts when the body is at rest 
(„rest and digest“ activities). Chronic sympathetic overactivity is related to multiple 
cardiovascular diseases (Fisher et al. 2009). The importance of afferent neural 
pathways in cardioprotection has been proved on animal models, where sec-
tioning of peripheral limb nerves or vagus nerve abolished the protective effect 
of RIPC (Donato et al. 2013). In the same study the electrical stimulation of vagus 
nerve was shown to mimic the cardioprotective effect of RIPC and administration 
of the antimuscarinic drug atropine was shown to reduce that effect, indicating 
the involvement of vagus nerve and muscarinic receptors (parasympathetic nervous 
system) in the mechanism of RIPC.  
 
 
2.2.2.2. Opioid receptors 
Opioid receptors are widely expressed in brain, spinal cord and multiple peripheral 
organs and are known for their role in pain modulation. During RIPC procedure, 
endogenous opioids such as endorphins, enkephalins and dynorphins are released 
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to cause activation of opioid receptors that are found to be involved in mediating 
the protective effect of RIPC (Aulakh et al. 2017). Opioids released into the 
bloodstream act on myocardial opioid receptors that possibly also mediate the 
cardioprotective effects (Randhawa and Jaggi 2017b).  
 
 
2.2.2.3. Adenosine and bradykinin 
Adenosine is a nucleoside that is found in different forms in all cells of the human 
body. It is locally released during RIPC and stimulates sensory nerve endings and 
activates the neural pathway, which leads to the cardioprotective effect, possibly 
by activating the myocardial adenosine receptors (Dong et al. 2004). Intraarterial 
infusion of adenosine has produced cardioprotection similar to RIPC, supporting 
its importance in the mechanism (Liem et al. 2002). 
Bradykinin is a proinflammatory peptide that acts on endothelial receptors, 
causing vasodilatation. Similarly to adenosine, bradykinin is released locally 
during RIPC procedure and participates in activating afferent neural pathways 
that evoke the cardioprotective effect (Ng et al. 2019). Likewise, its intraarterial 
infusion has been shown to induce cardioprotection (Schoemaker and van 
Heijningen 2000). 
 
 
2.2.2.4. TRPV1 channels 
Transient receptor potential vanilloid 1 (TRPV1) channels are a part of the 
transient receptor potential family of ion channels. These channels are expressed 
in sensory nerve cells, innervating cardiovascular system, and are most often 
associated with sensation of temperature and pain. They are also involved in 
regulating calcium signalling, which makes them important in multiple cellular 
processes (Aneiros et al. 2011). Activation of TRPV1 channels in RIPC is thought 
to be involved in mediating the cardioprotective effect through stimulating the 
release of calcitonin gene-related peptide and substance P (Randhawa and Jaggi 
2017a). Activation of TRVP1 channels has also some anti-inflammatory effects: 
it reduces the generation of free radicals, inhibits the production of inflammatory 
cytokines and recruitment of inflammatory cells, as well as stimulates the pro-
duction of anti-inflammatory cytokines (Bujak et al. 2019). Administration of the 
TRPV1 agonist capsaicin has been shown to enhance the protective effect of RIPC, 
while its antagonist capsazepine seems to abolish it (Randhawa and Jaggi 2017a).  
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2.3. Confounders to ischaemic conditioning 
2.3.1. Age 
As multiple studies have reported no effect of ischaemic conditioning, a range of 
possible confounders have been highlighted, which may explain overall neutral 
results. One of these confounders is age. It has been suggested that the release of 
cardioprotective humoral factor(s) into the blood may be age-dependent (Heinen 
et al. 2018). Although aged patients are at greater risk for many diseases and 
complications and need protective measures, the effect of RIPC may be reduced 
or abolished with aging. In animal studies, the cardioprotective effect of RIPC 
has been found to disappear in aged rats (Behmenburg et al. 2017). Also, plasma 
from aged preconditioned volunteers did not have any protective effects on rat 
heart, while plasma from young preconditioned volunteers was found to initiate 
cardioprotection (Heinen et al. 2018). Interestingly, plasma from the young had 
also an effect on aged heart. Additionally, in a meta-analysis, the nephropro-
tective effect of RIPC was found to be more pronounced in younger patients 
(Zhou et al. 2017). However, a large-scale clinical trial, which failed to show the 
effectiveness of RIPC in heart surgery patients, did not suggest that age is a 
confounding factor (Hausenloy et al. 2015). 
 
  
2.3.2. Gender 
Gender has been suggested to be a potential confounder, however human studies 
assessing differences in the effect of RIPC between the genders are lacking. In 
animal studies, females have been found to experience a weaker (Penna et al. 2009; 
Ciocci Pardo et al. 2018) or no effect (Dow and Kloner 2007; Sachdeva et al. 
2014; Heinen et al. 2018) of RIPC. Yet, a recent study on rat hearts demonstrated 
no difference in cardioprotection by RIPC between the genders (Lieder et al. 
2019). In addition, a retrospectively analysed human study did not reveal any 
differences in the effect of IPC in cardioprotection (Kleinbongard et al. 2016). 
 
 
2.3.3. Diabetes 
There is some evidence that diabetes might decrease the effect of RIPC. Moretti 
et al. found that the nephroprotective effect of RIPC is not present in diabetic 
patients (Moretti et al. 2018). Additionally, RIPC showed no protection in hyper-
glycaemic endothelial cells in vitro (Schenning et al. 2015) and no cardiopro-
tection in diabetic rats compared to normoglycaemic rats (Wider et al. 2018). 
Also, it has been suggested that diabetes reduces the cardioprotective effect of 
RIPostC, but does not completely abolish it (Oosterlinck et al. 2013). Jensen et 
al. showed that diabetes abolishes the cardioprotective effect of RIPC already at 
the cost of chronic activation of cardioprotection by circulating O-linked β-N-
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acetylglucosamine (O-GlcNAc) with no additional effect by RIPC in diabetic 
patients (Jensen et al. 2013). Nevertheless, diabetic patients with concomitant PAD 
have experienced positive effects of RIPC (Shahvazian et al. 2017) and improve-
ment of endothelial function (Maxwell et al. 2019). Moreover, a meta-analysis 
showed that RIPC even tended to strengthen its nephroprotective effect in these 
trials with a high percentage of participants with diabetes mellitus (Hu et al. 2016). 
 
 
2.3.4. Anaesthesia and the role of propofol 
The most widely discussed confounder to the effect of RIPC is supposedly 
propofol. Two large studies with patients undergoing cardiac surgery blamed 
propofol for their negative results (Hausenloy et al. 2015; Meybohm et al. 2015). 
Also, a meta-analysis revealed that the protective effect of RIPC against AKI was 
present only in a subgroup of the studies where propofol was not used (Pierce et 
al. 2017). Loss of cardioprotection due to the use of propofol has also been 
reported in animal trials (Behmenburg et al. 2018; Bunte et al. 2019). In addition 
to propofol, sevofluran was also found to abolish the effect of RIPC in one study 
(Cho et al. 2019). However, isoflurane anaesthesia showed cardioprotective 
effects, while propofol did not (Kottenberg et al. 2012). Contrary to the above 
results, RIPC offered a positive effect on leakage of TnT in patients who were 
under propofol-anaesthesia compared to patients under volatile anaesthesia in a 
systematic review; still, the number of patients who received volatile anaesthesia 
was limited (Benstoem et al. 2018). It has been shown that propofol abolishes the 
effect of RIPC only if administered before ischaemia, but not immediately after 
it (Chen et al. 2020). Some possible explanations for propofol’s neutralising 
effect have been suggested. As propofol has a phenolic structure similar to that 
of the natural antioxidant α-tocopherol (Vasileiou et al. 2009) it has also anti-
oxidant properties (Gan et al. 2015). It has been proposed that the free radical 
scavenging ability of propofol might attenuate the effects of RIPC (Kottenberg et 
al. 2014). Additionally, propofol has been demonstrated to interfere with cardio-
protection by blocking the activation of the TRPV1 channel in cases of remote 
preconditioning of trauma via surgical incision (Yu et al. 2019). Since RIPC has 
also been found to activate TRPV1 channels (Kleinbongard et al. 2017), which 
contributes to myocardial salvage from ischemia-reperfusion injury (Heymann et 
al. 2017), propofol is likely to abolish the cardioprotective effect of RIPC by 
blocking the activation of these channels.  
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2.3.5. Regular medications 
Quite few studies have assessed possible confounding medications affecting 
RIPC. It has been described that beta-blockers may attenuate the cardioprotective 
effect of RIPC (Zhou et al. 2013). Statins have been found to have synergistic 
cardioprotective effects with RIPC through reducing the levels of pro-inflam-
matory and cardiospecific enzymes (El Desoky et al. 2016; Cho et al. 2019).  
 
 
2.4. Metabolomics  
Metabolites are essential for normal functioning of cells and their flux is influ-
enced by internal and external stimuli. Metabolomics (comprehensive analysis of 
metabolites) is an innovative way to study the mechanism and objectives of 
ischaemic conditioning. During recent years, metabolites, including those with 
low-molecular weight, have been increasingly used as diagnostic and prognostic 
tools in clinical science. For example, in addition to traditional risk factors for 
atherosclerotic cardiovascular disease, the metabolome at large has been pro-
gressively studied. The metabolomic signatures differ between patients with 
advanced atherosclerosis and clinically healthy controls (Zagura et al. 2015). In 
particular, the levels of acylcarnitines (ACs) are different in patients with various 
stages of PAD and in those without PAD (Ismaeel et al. 2019). There are limited 
number of studies that have assessed the effect of RIPC on low-molecular weight 
metabolites. The effect of RIPC on amino acids and biogenic amines that are 
mainly involved in energy metabolism has been described (Chao de la Barca et 
al. 2016; Olenchock et al. 2016; Wang et al. 2018). The effect of RIPC is thought 
to be attained via multiple combined factors. Although there are some data about 
the actions of RIPC their exact mechanisms, including the actions on the meta-
bolome, are still unknown.  
 
 
2.4.1. Acylcarnitines 
ACs are esters of L-carnitine and fatty acids and due to the existence of different 
fatty acids (Wishart et al. 2018), a large set of ACs, generally divided into short, 
medium and long chain ACs (denoted as SCACs, MCACs and LCACs), can be 
produced. For the transportation of fatty acids into mitochondria for beta-
oxidation, the coenzyme A group is attached and is displaced further by carnitine 
to form acylcarnitine. The latter is able to enter the mitochondrial matrix, where 
it can be broken down by carnitine palmitoyl transferase II to release activated 
fatty acid to enter the process of beta-oxidation (McGill et al. 2014). It is crucial 
to produce LCACs as the mitochondrial inner membrane is impenetrable for long 
chain fatty acids. The increase of LCACs is most commonly associated with 
metabolic disorders such as mitochondrial dysfunction and genetically determined 
enzyme deficiencies. Based on previous studies, decrease of the levels of ACs 
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can be associated with preserved mitochondrial function (Bjørndal et al. 2018), 
whereas their increase has been linked to increased mortality in patients with 
chronic heart failure (Reuter and Evans 2012) and to worse prognosis in those 
with IgA nephropathy (Makrecka-Kuka et al. 2017). Several carnitine esters and 
members of the ACs’ family are elevated in patients with PAD (Ismaeel et al. 
2019). Nevertheless, the impact of ACs in clinical practice is unknown as relevant 
studies are lacking. Considering the results of the studies published on ACs, the 
knowledge of the ACs profile may facilitate assessment of the patients’ general 
metabolic milieu, mitochondrial functioning and prognosis.  
Plasma ACs have a different origin. The main precursors of SCACs are 
branched chain amino acids (BCAAs), but some SCASs are also produced by the 
catabolism of glucose and some triglycerides. MCACs and LCACS are only 
derived from fatty acid metabolism, whereas carnitine is required for transporting 
long-chain fatty acids into mitochondria (Makrecka-Kuka et al. 2017). Plasma 
SCASs have been found to be released from the liver (Schooneman et al. 2015), 
MCACs, from the skeletal muscles and liver (Xu et al. 2016) and LCACs from 
the heart (Makrecka-Kuka et al. 2017). Summing up, although the exact origin of 
plasma ACs is not clear, basing on assessment of the whole ACs spectrum, 
conclusions can be drawn about whole-body acylcarnitine metabolism. 
 
 
2.5. Summary of the literature review 
RIPC is an experimental procedure in which short episodes of ischaemia are 
induced in order to offer protection to the tissues of distant organs. Protective 
effects of RIPC for heart, kidneys and other organs, as well as to tissues sensitive 
to ischaemia have been described in procedures where ischaemia-reperfusion 
injury occurs. Nevertheless, the results are still quite contradictory. The exact 
mechanisms of RIPC are unknown, but multiple neural and humoral pathways 
along with biochemical markers involved in achieving the effect of RIPC have 
been discovered during recent decades. However, still little is known about the 
effects of RIPC on arterial stiffness and metabolomics, and only a few studies 
have assessed the impact of RIPC on vascular surgery. The most effective 
protocol of RIPC has not yet been established, although protocols consisting of 
3–4 cycles of 5-minute ischaemia are most commonly used. It is not clear who 
and under what circumstances will benefit the most from RIPC, but some possible 
confounders have been described: age, gender, concomitant diseases and certain 
medications. 
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3. AIMS OF THE THESIS  
The general aim of this thesis was to evaluate the effect of RIPC on multiorgan 
(arteries, heart, kidneys) salvage and on acylcarnitines’ metabolism in association 
with vascular surgery and to find out associations between the achieved effect 
and the clinical characteristics of the patients. 
 
Specific aims: 
1. To evaluate the effects of RIPC on arterial stiffness in patients undergoing 
vascular surgery 
2. To assess the effect of RIPC on the cardiospecific biomarkers and to establish 
clinical characteristics associated with these biomarkers in patients under-
going vascular surgery  
3. To estimate the effect of RIPC on kidney biomarkers in patients undergoing 
lower limb revascularisation surgery 
4. To measure the effect of RIPC on acylcarnitines’ metabolism in patients 
undergoing vascular surgery 
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4. SUBJECTS AND METHODS 
4.1. Study group 
Patients undergoing open surgery for repair of infra-renal AAA or surgical lower 
limb revascularisation surgery (for intermittent claudication or critical limb 
ischaemia, common femoral artery endarterectomy, aorto(bi)femoral or femoro-
popliteal or femorotibial or iliofemoral bypass surgery) or carotid endarterectomy 
(for symptomatic or asymptomatic carotid stenosis) were enrolled non-con-
secutively. Signed informed consent was obtained from each patient. The study 
was carried out at the Department of Vascular Surgery, Clinic of Surgery, Tartu 
University Hospital, from January 1, 2016 to February 8, 2018. 
The exclusion criteria were the following: age under 18 years, pregnancy, 
known malignancy in the past 5 years, permanent atrial fibrillation or flutter, 
symptomatic upper limb atherosclerosis, the need for oxygen therapy at home, 
estimated preoperative glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2, 
myocardial infarction in the past month, previous history of upper limb vein 
thrombosis or vascular surgery in the axillary region, and inability to follow the 
study regimen. 
 
 
4.2. Study design and eligibility 
This was a one-centre, prospective, randomised double-blinded sham-controlled 
clinical trial. The study was approved by the Research Ethics Committee of the 
University of Tartu (protocol nr 252/M-24), and was registered in the 
ClinicalTrials.gov database (NCT02689414). 
 
 
4.3. Methods 
4.3.1. Intervention 
The protocol of RIPC consisted of four 5-minute episodes of ischaemia, which is 
one of the most commonly described protocols in previous studies (Zarbock and 
Kellum 2016; Zhou et al. 2017). The intervention was performed with a blood 
pressure cuff on an upper arm. Ischaemia was achieved by raising cuff pressure 
to 200 mm Hg or, when the patient’s blood pressure exceeded 180 mm Hg, to a 
value that was 20 mm Hg higher than the value of his/her systolic blood pressure. 
Patients’ blood pressure was measured at the same time on the contralateral arm 
with the blood pressure cuff or directly via a cannula needle in an artery. In the 
sham group, the pressure in the cuff was equal to venous pressure (10–20 mm Hg). 
Between all episodes, there was a 5-minute period of reperfusion. The inter-
vention was started along with preparation for anaesthesia in the operating 
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theatre. Participation in the study did not influence any other aspects of treatment 
(surgery, anaesthesia or medication use). The author of this academic dissertation 
who was the principal investigator and was responsible for enrolment of patients, 
for performing the intervention and for data storage. 
 
 
4.3.2. Randomisation 
Randomisation was accomplished using a block design with block size 2 or 4 and 
stratification. The WINPEPI (PEPI-for-Windows) computer program was used 
to generate a random allocation sequence. Patients were stratified by surgery 
(aneurysm repair or other), age (under or over 65 years) and the American Society 
of Anaesthesiologists’ (ASA) physical status classes 2, 3 or 4. By using these 
differentia, 16 strata were created. The allocation letter was kept in an opaque 
sealed envelope and opened immediately before the intervention when patients 
arrived in the operating theatre. Randomisation and the opaque sealed envelopes 
were arranged by a third party. Patients were randomly allocated at a ratio of 1:1 
in parallel to the RIPC or the sham group.  
 
 
 4.3.3. Blinding 
The patient, patient’s physician, surgeon, anaesthesiologist and everyone else in 
the surgical team were blinded to study intervention. The principal investigator 
(T.K.) was responsible for performing the intervention and while keeping the 
scale of the manometer concealed throughout the intervention. In principle, 
patients were able to feel pressure in the cuff, but their group affiliation and the 
pressure required to achieve preconditioning was not revealed to them. The 
statistician was blinded to the meaning of group affiliation. 
 
 
4.3.4. Outcomes 
The co-primary outcomes were augmentation index (AIx) and carotid-femoral 
pulse wave velocity (PWV).  
The secondary outcomes were: 
o arterial elasticity indices  
o central and peripheral blood pressure and heart rate 
o cardiac biomarkers: high sensitivity troponin T (hs-TnT) and N-terminal pro 
b-type natriuretic peptide (NT-proBNP);  
o traditional biomarkers of renal function: urea and creatinine;  
o novel biomarkers of renal function: neutrophil gelatinase-associated 
lipocalin (NGAL), liver-type fatty acid binding protein (L-FABP), kidney 
injury molecule-1 (KIM-1), cystatine C, beta-2 microglobulin;  
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o markers of inflammation and oxidative stress: oxidized low-density 
lipoprotein (oxLDL), interleukin-18 (IL-18), myeloperoxidase (MPO), 
isoprostanes 
o acylcarnitines 
o complications of remote ishcaemic preconditioning: upper-extremity deep 
vein thrombosis, acute upper limb ischaemia. 
 
 
4.3.4.1. Biochemical analysis of blood and urine 
  
4.3.4.2. Targeted serum metabolite profiling 
The levels of low-molecular weight metabolites were analysed using the 
AbsoluteIDQp180 kit (Biocrates Life Sciences AG, Innsbruck, Austria). The 
analytical procedure was performed according to the manufacturer’s standard 
protocol in the laboratory of the Department of Biochemistry, University of 
Tartu. In brief, for targeted analysis of metabolites, the internal standard was 
pipetted onto a 96-well extraction plate and 10 µL of serum was added to each 
well. Drainage was achieved with nitrogen and derivatisation was performed with 
phenyl isothiocyanate. Measurements were accomplished with QTRAP 4500 
(ABSciex, USA) coupled to an Agilent 1260 series HPLC (USA) using the C18 
column and flow injection analysis. The vendor’s software with internal standards’ 
intensities was used to calculate the concentrations of metabolites. 
 
 
4.3.4.3. Parameners of arterial stiffness and peripheral and  
central haemodynamics 
Arterial stiffness was evaluated with measurements of carotid-femoral PWV, AIx 
and small and large artery elasticity indices. PWV and AIx were measured with 
Sphygmocor XCEL PWA and PWV (AtCorMedical, Sydney, Australia) pre-
Blood samples were collected in the morning of surgery, and at 2 hours, 8 hours 
and at approximately 24 hours of surgery, and urine samples were collected in the 
morning of surgery and 24 hours after surgery. The last blood and urine collection 
was set as close as possible to 24 hours after surgery provided that the patient had 
fasted for at least 3 hours. Analysis of hs-TnT, NT-proBNP, cholesterol, high-
density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, 
creatinine, urea, beta-2 microglobulin, cystatin C, hs-CRP and complete blood 
count were analysed in the United Laboratories of Tartu University Hospital. 
Serum for analysis of oxLDL, IL-18, MPO, NGAL was extracted after centri-
fugation and stored in the refrigerator at –80 °C until measurements in the 
laboratory of the Department of Biochemistry, University of Tartu. Urine samples 
for analysis of isoprostanes, creatinine, L-FABP and KIM-1 were also centrifuged 
and stored in the refrigerator at –80 °C and analysed in the same laboratory. 
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operatively and approximately 24 hours postoperatively. The measurements were 
carried out in the resting state with the patient having fasted and not having 
smoked for at least three preceding hours. For AIx assessment, the brachial wave-
form was captured by the machine inflating the cuff partially. The central aortic 
waveform and pulse wave analysis were generated by SphygmoCor Brachial 
GTF. The AIx, AIx@75, central blood pressure, pulse pressure, and mean arterial 
pressure were provided. Two or three measurements were performed. If the 
difference between two measurements was greater than 2 units (%) in the case of 
AIx and/or 1 unit (%) in the case of AIx@75, a third measurement was performed 
and the median value of three measurements was used for final analysis. The 
median value was to reduce the possible impact of one dissimilar measurement. 
Otherwise, the mean value of two measurements was used. For blood pressure 
and heart rate, the mean value of two or three measurements was used in the final 
analysis. 
For PWV assessment, femoral and carotid pulse waves were recorded simul-
taneously. The femoral waveform was captured by the machine inflating the cuff 
partially over the thigh. The carotid waveform was captured by applanation tono-
metry. At least two quality PWV measurements with a maximum difference of 
0.5 m/s were obtained and the mean value of these measurements was used for 
the final analysis. 
The elasticity indices of large (C1) and small (C2) arteries were obtained non-
invasively using the HDI/PulseWave CR-2000 research CardioVascular Profiling 
System (Hypertension Diagnostics, Inc., MN, USA). At least two quality measure-
ments were required with a maximum difference of 2 in C2 and 3 in C3. The 
mean value of these measurements was used for the final analysis. 
 
 
4.3.5. Statistical analysis 
Sample size calculation was performed based on one of the co-primary outcomes – 
AIx@75. As no previous studies had dealt with the effect of RIPC on AIx@75 or 
other parameters of vascular stiffness, no data required for calculation of sample 
size were available. Hence, sample size was calculated based on the data of the 
first 30 participants. Also, as the postulated prediction was unidirectional, one-
tailed Welch’s t test was used for calculation of sample size. The desired study 
power was set at 80% and the magnitude of the effect to be obtained was 5% of 
the difference in AIx@75 between the study group and the sham group. The 
calculated sample size was 44 for each group.  
Categorical variables were compared with Pearson’s chi-square test. The 
difference of continuous variables between two groups were compared using the 
two sample t-test for data with a normal distribution or with the Wilcoxon rank 
sum test in the case of a data with a non-normal distribution. The significance of 
change of continuous variables within one group was calculated with the paired 
T-test for data with normal distribution or Wilcoxon signed rank test in the case 
of a data with non-normal distribution. For statistical analysis of multiple 
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repeated measures, analysis of variance (ANOVA) or multivariate analysis of 
variance (MANOVA) for repeated measures was used. For assessing correlations 
between cardiac enzymes and other clinical parameters, Spearman’s correlation 
coefficient was employed. All tests were performed as two-way tests. Data with 
a normal distribution is presented as mean and standard deviation (SD) and data 
with a non-normal distribution is presented with median and interquartile range.  
For correction for multiple comparisons, Benjamini-Hochberg procedure was 
used to control false discovery rate. A p value of < 0.05 was considered to be 
indicative of statistical significance. Kolmogorov-Smirnov test was used for 
testing the normality of distribution. 
Statistical analysis was performed by a qualified statistician of the University 
of Tartu.  
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5. RESULTS 
Ninety-eight patients were recruited and randomised into study groups. After 
dropouts, the data of 45 patients in the RIPC group and 48 patients in the sham 
group was used in the final data analysis. The detailed patient flow is shown in 
Figure 1. The reason for not measuring arterial stiffness twice was the patient’s 
stay in the intensive care unit. In 42 patients (93%) of the RIPC group and in 45 
(96%) patients of the sham group, blood was collected at all time points: 
preoperatively and at 2 hours, 8 hours and 24 hours postoperatively. In 3 patients 
of the RIPC group and in 2 patients of the sham group, blood collection was 
missed either at 2 hours or 8 hours after surgery. The median time from the end 
of the intervention to the beginning of surgery did not differ significantly 
(p=0.057) between the RIPC (36 min, IQR 21–46 min) and the sham group 
(25 min, IQR 15–38 min). The change in eGFR through all time points was 
similar between the groups (p=0.369). The median change in eGFR from baseline 
to 24 hours postoperatively was 2 mL/min/1.73m2 (IQR –3–5 mL/min/1.73m2; 
 
 
Figure 1. Patients’ flow chart for the remote ischaemic preconditioning (RIPC) group 
and the sham group in vascular surgery 
Patients randomised 
n=98 
FINAL ANALYSIS n=45 
- carotid endarterectomy n=9 
- open aortic surgery n=8 
- lower limb revascularisation surgery n=28 
 
Data exclusion for analysis based on 
arterial stiffness parameters 
- In 1 patient second arterial stiffness 
assessment was not performed 
DROPOUT 
- 1 patient underwent resurgery 
before termination of the trial 
 
FINAL ANALYSIS n=48 
- carotid endarterectomy n=12 
- open aortic surgery n=7 
- lower limb revascularisation surgery n=29 
 
Data exclusion for analysis based on blood 
samples 
- 1 patient refused from repeat blood 
sampling 
 
Data exclusion for analysis based on 
arterial stiffness parameters 
- In 2 patients second arterial stiffness 
assessment was not performed 
DROPOUT 
- 1 patient underwent resurgery 
before termination of the trial 
- 2 surgeries were cancelled 
- 1 early discontinuation due to 
prolonged hypotension after 
induction of anaesthesia 
Patients allocated to 
sham n=49
Patients allocated to 
RIPC n=49 
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p=0.401) in the RIPC group and 1 ml/min/1.73m2 (IQR –8–5 mL/min/1.73m2; 
p=0.393) in the sham group with no significant difference between the groups 
(p=0.348). The baseline characteristics of the two groups were similar (Table 1) 
and there were no significant differences between the groups regarding the 
characteristics of surgery (Table 2). No patient experienced complications of RIPC 
(upper-extremity deep vein thrombosis, acute upper limb ischaemia) nor 
considered the procedure intolerable. 
 
Table 1. Baseline characteristics of the vascular surgery patients allocated to remote 
ischaemic preconditioning (RIPC) or sham procedure 
Variable RIPC (n=45) SHAM (n=47) p-value 
Age, years (SD) 67 (±9) 66 (±10) 0.577 
Male, n (%) 36 (80) 32 (68) 0.288 
BMI, kg/m2 (SD) 26.3 (±6.4) 26.5 (±6.7) 0.840 
ASA 2, n (%) 18 (40) 19 (40) 1 
ASA 3, n (%) 20 (44) 22 (47) 0.986 
ASA 4, n (%) 7 (16) 6 (13) 0.933 
ACEI or ARB, n (%) 21 (47) 30 (64) 0.148 
Calcium channel blockers, n (%) 9 (20) 17 (37) 0.135 
Beta-blockers, n (%) 11 (24) 19 (40) 0.158 
Statins, n (%) 13 (29) 14 (30) 1 
Diabetes, n (%) 5 (11) 8 (17) 0.607 
Myocardial infarction, n (%) 8 (18) 3 (6) 0.172 
Stroke, n (%) 10 (22) 12 (26) 0.899 
Smoker (current or ex-smoker), n (%) 40 (89) 42 (89) 1 
PSBP, mm Hg (SD) 143 (±18) 141 (±16) 0.537 
PDBP, mm Hg (SD) 78 (±11) 79 (±11) 0.674 
CSBP, mm Hg (SD) 131 (±15) 130 (±14) 0.634 
CDBB, mm Hg (SD) 79 (±11) 81 (±11) 0.522 
MAP, mm Hg (SD) 99 (±12) 100 (±11) 0.678 
Heart rate, bpm (SD) 66 (±9) 67 (±11) 0.754 
Cholesterol 5.0 (4.2–5.7) 5.0 (3.9–5.6) 0.793 
LDL 3.4 (8.1–10.4) 3.3 (2.5–3.8) 0.500 
HDL 1.1 (0.9–1.4) 1.1 (1.0–1.3) 0.311 
Triglycerides 1.6 (1.3–1.8) 1.5 (1.2–2.0) 0.787 
AIx, % (SD) 36 (±11) 34 (±13) 0.467 
AIx@75, % (SD) 32 (±11) 30 (±13) 0.517 
PWV, m/s (IQR) 9.4 (8.1–10.4) 8.7 (7.9–9.8) 0.233 
BMI – body mass index; ASA – American Society of Anaesthesiologists’ physical status score; 
ACEI – angiotensin-converting-enzyme inhibitor; ARB – angiotensin II receptor blocker; PSBP – 
peripheral systolic blood pressure; PDBP – peripheral diastolic blood pressure; CSBP – central 
systolic blood pressure; CDBP – central diastolic blood pressure; MAP – mean arterial blood 
pressure; AIx – augmentation index; AIx@75 – augmentation index corrected for a heart rate of 75 
beats per minute; PWV – pulse wave velocity; SD – standard deviation; IQR – interquartile range
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Table 2. Characteristics of vascular surgery of patients allocated to remote ischaemic 
preconditioning (RIPC) or sham procedure 
 RIPC (n=45) SHAM (n=47) p-value 
General anaesthesia, n (%) 24 (53) 28 (60) 0.6941 
Spinal anaesthesia, n (%) 21 (47) 18 (38) 0.548 
Intravenous anaesthesia, n (%) 0 1 (2) 1 
Administration of propofol, n (%) 19 (42) 26 (55) 0.295 
Carotid endarterectomy, n (%) 9 (20) 12 (26) 0.701 
Lower limb revascularisation, n (%) 28 (62) 28 (60) 0.963 
Open aortic aneurysm repair, n (%) 8 (18) 7 (15) 0.927 
Infusion during surgery, ml (IQR) 1200  
(1000–2100) 
1350  
(1000–1600) 
0.858 
Blood loss during surgery, n  
(%; average ml) 
8 (18; 1157) 13 (28; 754) 0.379 
Duration of surgery, min (IQR) 108 (89–135) 112 (84–156) 0.827 
Hospitalisation to 3rd level intensive 
care unit, n (%; average days) 
1 (2; 4) 4 (9; 2.25) 0.384 
IQR ─ interquartile range 
 
 
5.1.1. Comparison between the groups: effects of RIPC 
The baseline values of arterial stiffness parameters did not differ between the 
groups (Table 1). There were no significant differences between the RIPC and 
sham groups, regarding changes 24 h post-operatively, in AIx (p=0.828), AIx@75 
(p=0.837), PWV (p = 0.701), C1 (p=0.785), C2 (p=0.635), or mean arterial 
pressure (MAP, p=0.676).  
 
 
5.1.2. Post-operative changes within the RIPC and the sham group 
There were significant improvements at approximately 24 h post-operatively in 
AIx, AIx@75, and C2 within both groups, but changes of PWV and C1 were not 
significant (Figure 2). In the RIPC group, changes of the arterial stiffness 
parameters were as follows: PWV mean change –0.3 m/s, (SD 1.7); AIx median 
change –5.8 %, (IQR –15–0); AIx@75 median change –2.5%, (IQR –9.8–0.5);  
C1 median change 0.5 mL/mmHg × 100, (IQR –1.6–3.7; C2 median change 
0.7 mL/mmHg × 100, (IQR 0–3.4). In the sham group, the changes in the arterial 
stiffness parameters were the following: mean change in PWV –0.4 m/s, 
(SD 1.4); median change in AIx –5.5%, (IQR –13.5–0.5); median change in 
AIx@75 –2%, (IQR –10.0–1.0); median change in C1 0.1 mL/mmHg × 10, 
(IQR –1.7–2.5); median change in C2 0.85 mL/ mmHg × 100, (IQR 0–2.2). All 
haemodynamic changes were statistically significant in both groups (Figure 3). 
5.1. Effect of RIPC on arterial stiffness (Paper I) 
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Figure 2. Changes in the arterial stiffness parameters in the remote ischaemic 
preconditioning (RIPC) group and in the sham group in vascular surgery. AIx – 
augmentation index (%); AIx@75 – augmentation index corrected for heart rate of 75 
beats per minute (%); PWV – pulse wave velocity (m/s); C1 – large artery elasticity index; 
C2 – small artery elasticity index. 
Figure 3. Changes in the haemodynamic parameters in the remote ischaemic pre-
conditioning (RIPC) group and in the sham group in vascular surgery. MAP – mean artrial 
pressure; CSBP – central systolic blood pressure; CDBP – central diastolic blood pressure; 
PSBP – peripheral systolic blood pressure; PDBP – peripheral diastolic blood pressure.  
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5.2.1. Hs-Troponin T 
The baseline hs-TnT did not differ statistically (p=0.900) between the RIPC 
group (median 10.4 ng/L IQR 7.1–14.7 ng/L) and the sham group 10.5 ng/mL 
(IQR 7.2–15.3 ng/L). Hs-TnT increased significantly more in the sham group 
compared to the RIPC group during follow-up at 2 hours, 8 hours and 24 hours 
after surgery (p<0.001, Figure 4). Also, the difference in the peak change of  
hs-TnT between the RIPC group (median change 0.6 ng/L; IQR –0.7–2.1 ng/L) 
and the sham group (median change 2 ng/L; IQR 0.9–6.2 ng/L) was statistically 
significant (p=0.003). With regard to within-group differences, the increase of 
hs-TnT from the baseline to its maximum value was statistically significant in 
both groups (p<0.001). 
Figure 4. Changes in cardiac biomarkers in the remote ischaemic preconditioning (RIPC) 
group and in the sham group in vascular surgery A Changes in high-sensitivity troponin 
T across the time points B Changes in N-terminal pro b-type natriuretic peptide  
(NT-proBNP); *p-value for the change in the RIPC group; ** p-value for the change in 
the sham group;***p-value for the changes between the groups 
 
 
5.2.2. NT-proBNP 
The baseline median NT-proBNP value was 99 pg/mL (IQR 56─232 pg/mL) in 
the RIPC group and 143 pg/mL (IQR 63─312 pg/mL) in the sham group (p=0.419). 
A significant increase of NT-proBNP was noted both in the RIPC (median 
increase 51 pg/mL, IQR –12–196 pg/mL) and sham groups (median increase 
144 pg/mL, IQR 17–318 pg/mL, Figure 4). The difference in the increase bet-
ween the groups was statistically significant (p=0.020).  
 
 
 
 
 
5.2. Effect of RIPC on cardiac damage biomarkers (Paper II) 
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5.2.3. Cardiac complications  
Two patients were diagnosed with decompensation of heart failure and a new 
onset of atrial fibrillation was diagnosed in one of them. In the other patient, a 
marked increase of hs-TnT (596 ng/L) was detected, but there were no ECG 
changes, nor did the patient have angina. Both of these patients were from the 
sham group. No patient was diagnosed with perioperative myocardial infarction. 
Four patients in the sham group and one patient in the RIPC group were 
hospitalised to a 3rd level intensive care unit after surgery (p=0.384). There were 
no statistically significant differences between the groups regarding the charac-
teristics of surgery (Table 2).  
 
 
5.2.4. Correlations between cardiac biomarkers and  
clinical parameters (Table 3) 
Positive correlation between gender (male<female) and increase of hs-TnT 
(ρ=0.36; p=0.015) and NT-proBNP (ρ=0.38; p=0.010) was established in the 
RIPC group. There was also correlation between increase of hs-TnT and baseline 
AIx (ρ=0.29; p=0.051) in the RIPC group. Negative correlation (ρ=–0.30; p=0.042) 
occurred between pretreatment with statins and increase of hs-TnT in the RIPC 
group. There was positive correlation (ρ=0.46; p=0.027) between increase of NT-
proBNP and increase of PWV in the sham group. Positive correlation occurred 
between administration of propofol and increase of NT-proBNP both in the RIPC 
group (ρ=0.46; p=0.001) and in the sham (ρ=0.37; p=0.012) group. Negative 
correlation was found between type of anaesthesia (general<spinal) and increase 
in NT-proBNP both in the sham (ρ=–0.34; p=0.019) and RIPC group (ρ=–0.36; 
p=0.016). Also, negative correlation occurred between hs-TnT and eGFR both in 
the RIPC group (ρ=–0.47, p=0.001) and in the sham group (ρ=–0.37, p=0.010) 
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5.3. Effect of RIPC on kidney biomarkers  
in the subgroup of patients undergoing lower  
5.3.1. The effect of RIPC on kidney biomarkers in serum and urine  
Creatinine increased significantly more in the sham group than in the RIPC group 
(p=0.021, Figure 5) through all time points (from baseline to 2, 8 and 24 hours 
after surgery). The eGFR decreased significantly more in the sham group 
(p=0.015, Figure 5). There was no significant change in urea between the groups 
through all time points (p=0.067, Figure 5). The change in cystatin C and beta-2 
microglobulin was significantly different between the groups (p-values 0.021 and 
0.024, respectively, Figure 5). Creatinine, cystatin C, and beta-2 microglobulin 
increased and eGFR decreased significantly more in the sham group than in the 
RIPC group through all time points (p= 0.021, p=0.024, p=0.021, and p=0.015, 
respectively, Figure 5). The change in NGAL levels did not differ between the 
groups (p=0.174). When comparing the two timepoints, baseline and 24 hours 
after surgery, the increase in creatinine, eGFR, urea, cystatin C and beta-2 micro-
globulin was significantly smaller in the RIPC group (p=0.003, p=0.005, p=0.041, 
p=0.022, p=0.033, respectively, Table 4). In 4 patients (14%) from the sham 
group and in 1 (4%) patient from the RIPC group, AKI could be diagnosed based 
on the KDIGO’s criteria, however, the difference was insignificant (p=0.604) 
The level of KIM-1 in urine increased significantly both in the RIPC group 
(change median 930, IQR –81–3078, p=0.001) and in the sham group (change 
median 1238, IQR -124–3097, p=0.006), but there was no difference between the 
groups (p=0.935). The change in urinary L-FABP level was not statistically 
significant in either group, nor was there any difference between the groups in 
this respect (p=0.710, Table 4). 
There was a significant increase in creatinine (p=0.011), eGFR (p=0.007), 
cystatin C (p=0.038) and beta-2 microglobulin (p=0.013) in the sham group 
through all time points (Figure 5). There was a significant decrease in urea 
(p=0.050, Figure 5) and a significant increase in NGAL (p=0.001) in the RIPC 
group through all time points. The change in creatinine, urea, cystatin C and beta-
2 microglobulin was not statistically significant in the RIPC group (p>0.05) and 
the change in urea and NGAL was not statistically significant in the sham group 
(p>0.05) (Table 4). 
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Figure 5. Statistically significant changes between the sham group and the remote 
ischaemic preconditioning (RIPC) group in creatinine, estimated glomerular filtration rate 
(eGFR), urea, cystatin C, beta-2 microglobulin and in the ratio of urinary isoprostanes to 
creatinine in patients undergoing lower limb revascularisation surgery. *p-value for the 
change in the RIPC group; ** p-value for the change in the sham group; ***p-value for 
the changes between the groups 
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5.4.1. Changes in the levels of ACs in the RIPC and  
sham groups (Table 5) 
A significant decrease (p<0.05) was detected both in the sham and the RIPC 
group in the levels of the following ACs: C2, C8, C10, C10:1, C12, C12:1, C14:1, 
C14:2, C16, C16:1, C18, C18:1, C18:2. In the sham group, there was a significant 
increase (p<0.05) in the levels of C0 (carnitine) and a significant decrease in the 
level of C18:1-OH. In the RIPC group, a significant decrease (p<0.05) was noted 
in the levels of C3-OH, C3-DC (C4-OH), C6:1, C9, C10:2. There was a signi-
ficant difference between the groups regarding the changes in C3-OH (p=0.023): 
there was a significant decrease (–0.007 µmol/L, SD 0.020 µmol/L, p=0.023) in 
the RIPC group and an insignificant increase (0.002 µmol/L, SD 0.015 µmol/L, 
p=0.481) in the sham group. 
 
Table 5. Changes in the levels of acylcarnitine esters from baseline to 24 hours after 
vascular surgery in the remote ischaemic preconditioning (RIPC) group and in the sham 
group. Data are shown as mean change ± standard deviation.  
 
SHAM RIPC RIPC vs 
SHAM 
p-value 
Change 
(µmol/L) 
p-
value 
Change 
 (µmol/L) 
p-
value 
C0 5.094 (±14.137) 0.017 4.211 (±14.795) 0.063 0.706 
C2 –1.137 (±3.082) 0.015 –1.258 (±2.862) 0.005 0.791 
C3 0.011 (±0.313) <0.001 –0.078 (±0.385) <0.001 0.243 
C3-DC –0.003 (±0.026) 0.394 –0.008 (±0.027) 0.049 0.723 
C3-OH 0.002 (±0.015) 0.481 –0.007 (±0.02)0 0.023 0.023 
C3:1 –0.000 (±0.015) 0.956 –0.002 (±0.017) 0.458 0.608 
C4 0.017 (±0.111) <0.001 –0.013 (±0.117) <0.001 0.204 
C4:1 0.002 (±0.015) 0.268 –0.003 (±0.018) 0.223 0.098 
C5 0.004 (±0.116) <0.001 –0.037 (±0.153) <0.001 0.055 
C5-DC (C6-OH) 0.001 (±0.030) 0.847 0.003 (±0.024) 0.427 0.724 
C5-M-DC 0.011 (±0.036) 0.050 0.008 (±0.039) 0.187 0.399 
C5-OH (C3-DC-M) –0.002 (±0.016) 0.468 –0.003 (±0.018) 0.350 0.677 
C5:1 0.001 (±0.014) 0.782 –0.004 (±0.022) 0.244 0.058 
C5:1-DC 0.003 (±0.014) 0.093 –0.002 (±0.016) 0.530 0.182 
C6 (C4:1-DC) –0.007 (±0.040) 0.242 –0.008 (±0.042) 0.203 0.764 
C6:1 –0.000 (±0.001) 0.871 –0.001 (±0.002) 0.048 0.107 
C7-DC –0.002 (±0.012) 0.183 –0.002 (±0.011) 0.215 0.903 
C8 –0.053 (±0.109) 0.002 –0.052 (±0.085) <0.001 0.966 
C9 0.000 (±0.019) 0.864 –0.008 (±0.021) 0.023 0.059 
C10 –0.103 (±0.166) <0.001 –0.115 (±0.183) <0.001 0.935 
5.4. Effect of RIPC on the levels of acylcarnitines (Paper IV) 
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SHAM RIPC RIPC vs 
SHAM 
p-value 
Change 
(µmol/L) 
p-
value 
Change 
 (µmol/L) 
p-
value 
C10:1 –0.030 (±0.054) <0.001 –0.033 (±0.043) <0.001 0.686 
C10:2 –0.002 (±0.021) 0.442 –0.009 (±0.021) 0.007 0.145 
C12 –0.026 (±0.062) <0.001 –0.026 (±0.048) <0.001 0.840 
C12-DC –0.007 (±0.026) 0.070 0.000 (±0.027) 0.914 0.180 
C12:1 –0.024 (±0.050) 0.002 –0.033 (±0.034) <0.001 0.216 
C14 –0.005 (±0.023) <0.001 –0.002 (±0.032) <0.001 0.904 
C14:1 –0.026 (±0.046) <0.001 –0.022 (±0.027) <0.001 0.938 
C14:1-OH 0.000 (±0.010) 0.826 –0.001 (±0.011) 0.510 0.518 
C14:2 –0.011 (±0.015) <0.001 –0.007 (±0.014) 0.002 0.153 
C14:2-OH –0.000 (±0.022) 0.938 0.002 (±0.013) 0.254 0.972 
C16 –0.036 (±0.040) <0.001 –0.029 (±0.035) <0.001 0.367 
C16-OH –0.002 (±0.012) 0.325 –0.003 (±0.017) 0.289 0.760 
C16:1 –0.012 (±0.018) <0.001 –0.010 (±0.017) <0.001 0.648 
C16:1-OH –0.003 (±0.009) 0.054 –0.003 (±0.011) 0.072 0.826 
C16:2 –0.003 (±0.018) 0.310 –0.002 (±0.017) 0.412 0.935 
C16:2-OH –0.001 (±0.008) 0.435 –0.000 (±0.009) 0.876 0.891 
C18 –0.494 (±0.787) <0.001 –0.619 (±0.990) <0.001 0.803 
C18:1 –0.057 (±0.051) <0.001 –0.050 (±0.043) <0.001 0.453 
C18:1-OH –0.006 (±0.014) 0.005 –0.000 (±0.016) 0.924 0.098 
C18:2 –0.015 (±0.015) <0.001 –0.018 (±0.016) <0.001 0.454 
 
 
5.4.2. Correlations between change in hs-TnT and  
changes in the levels of ACs (Table 6) 
In the RIPC group, there were significant positive correlations between change 
in hs-TnT and change in C4 (ρ=0.38, p=0.01), C10 (ρ=0.38, p=0.010), C10:1 
(ρ=0.38, p=0.010), C12:1 (ρ=0.31, p=0.037), C18:1 (ρ=0.32, p=0.030) and  
C18-OH (ρ=0.35, p=0.019). In the sham group, there was a significant negative 
correlation between change in hs-TnT and change in C5-OH (ρ= –0.34, p=0.021). 
No other significant correlations were observed between changes in the levels of 
hs-TnT and ACs in the sham group. 
 
 
5.4.3. Correlations between change in NT-proBNP and  
changes in the levels of ACs (Table 6) 
In the RIPC group, a significant positive correlation occurred between change in 
NT-proBNP and change in C16:2 (ρ=0.34, p=0.021). In the sham group, a signi-
ficant positive correlation occurred between change in NT-proBNP and change 
in C18 (ρ=0.31, p=0.031) and a significant negative correlation occured between 
change in NT-proBNP and change in C16:1 (ρ= –0.35, p=0.016)
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Table 6. Correlations between cardiac biomarkers (i.e.high sensitivity troponin T and 
NT-proBNP) and acylcarnitines for vascular surgery patients who were allocated to the 
remote ischaemic preconditioning (RIPC) or sham procedure 
 Hs-TnT NT-proBNP 
 RIPC 
(n=45) 
p* SHAM 
(n=47)
 
p* 
RIPC 
(n=45)
p* 
 
SHAM 
(n=47) 
p* 
C0 –0.08 0.608 –0.13 0.360 0.10 0.516 0.01 0.928 
C2 0.20 0.190 –0.07 0.638 0.03 0.855 0.18 0.236 
C3 0.202 0.184 0.20 0.18 –0.08 0.608 –0.04 0.765 
C3-DC 0.08 0.613 –0.01 0.935 0.13 0.411 0.06 0.748 
C3-OH 0.11 0.467 <0.01 0.983 –0.06 0.705 –0.01 0.958 
C3:1 0.06 0.706 0.05 0.730 0.18 0.246 –0.16 0.283 
C4 0.377 0.01 –0.05 0.734 0.10 0.532 –0.26 0.081 
C4:1 0.15 0.322 –0.04 0.764 0.18 0.230 –0.03 0.844 
C5 0.207 0.172 –0.07 0.630 0.04 0.770 0.07 0.621 
C5-DC 0.18 0.230 –0.29 0.050 0.15 0.320 –0.16 0.276 
C5-M-DC –0.08 0.588 –0.10 0.489 <0.01 0.976 –0.05 0.739 
C5-OH 0.13 0.379 –0.34 0.021 –0.06 0.719 0.14 0.359 
C5:1 –0.14 0.356 –0.02 0.874 0.13 0.403 –0.13 0.402 
C5:1-DC 0.07 0.647 –0.14 0.352 0.15 0.318 –0.19 0.208 
C6 0.24 0.119 0.04 0.788 –0.05 0.725 –0.01 0.960 
C6:1 0.19 0.206 0.08 0.581 0.16 0.309 –0.02 0.909 
C7-DC 0.07 0.639 –0.08 0.580 0.18 0.241 0.28 0.055 
C8 0.26 0.087 –0.15 0.323 0.24 0.112 0.05 0.754 
C9 0.26 0.086 –0.01 0.964 0.09 0.575 –0.02 0.904 
C10 0.38 0.010 –0.12 0.416 0.30 0.049 –0.10 0.519 
C10:1 0.38 0.010 –0.12 0.404 0.18 0.225 –0.12 0.405 
C10:2 0.04 0.795 –0.08 0.595 0.08 0.587 0.06 0.667 
C12 0.17 0.272 0.05 0.754 0.02 0.888 0.08 0.603 
12-DC –0.07 0.644 –0.10 0.50 –0.06 0.719 –0.17 0.251 
C12:1 0.31 0.037 –0.06 0.672 0.18 0.232 –0.04 0.797 
C14 0.06 0.691 –0.02 0.915 0.25 0.100 0.03 0.824 
C14:1 0.14 0.349 –0.11 0.444 0.15 0.311 –0.05 0.741 
C14:1-OH 0.10 0.531 –0.19 0.207 0.25 0.100 –0.208 0.160 
C14:2 0.22 0.140 –0.07 0.656 0.13 0.405 –0.23 0.120 
C14:2-OH –0.15 0.327 –0.09 0.559 –0.09 0.552 –0.05 0.757 
C16 –0.11 0.478 –0.08 0.584 0.06 0.691 –0.03 0.855 
C16-OH –0.22 0.147 0.10 0.516 0.09 0.554 0.08 0.587 
C16:1 –0.15 0.341 –0.25 0.090 0.10 0.500 –0.35 0.016 
C16:1-OH –0.10 0.521 0.24 0.112 0.19 0.217 0.14 0.364 
C16:2-OH 0.12 0.451 –0.13 0.370 0.13 0.396 –0.02 0.909 
C18 0.05 0.745 –0.11 0.476 0.17 0.268 0.315 0.031 
C18:1 0.32 0.030 –0.15 0.300 0.15 0.329 –0.13 0.389 
C18-OH 0.35 0.019 –0.07 0.628 0.12 0.431 –0.27 0.07 
C18:2 0.16 0.297 <0.01 0.995 0.14 0.359 –0.04 0.785 
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6. DISCUSSION 
6.1. Effect of RIPC on arterial stiffness during  
vascular surgery  
Studies that have assessed the effect of RIPC on arterial stiffness are limited while 
no study has assessed the effect of vascular surgery on arterial stiffness. As RIPC 
has been proven to have positive effects on endothelial function and on AIx 
(Zagidullin et al. 2016; Kuusik et al. 2019), its positive effect on arterial stiffness 
could be expected. 
Until today, evidence about the clinical significance of RIPC is lacking as most 
studies have either not had clinically relevant outcomes or have not presented 
positive results regarding clinical measures. PWV, the “gold standard” parameter 
of measuring arterial stiffness, has been shown to predict cardiovascular events 
and all-cause mortality (Vlachopoulos et al. 2010). If RIPC alters positively 
PWV, its clinical value would be evident. However, as PWV is a relatively constant 
parameter, it may need daily preconditioning for a longer period to reveal the true 
effect of RIPC. As RIPC has produced a positive effect on AIx (Zagidullin et al. 
2016; Kuusik et al. 2019), which is more labile parameter of arterial stiffness, 
then its effect on PWV is even more likely. Considering that our study (Paper I) 
demonstrated no effect of RIPC on any parameter of arterial stiffness, its true 
effect on arterial stiffness is hard to evaluate based on the present study. This can 
be due to a number of confounders that originate primarily from surgery and 
anaesthesia. Vascular surgery as a high-risk procedure is in needs protective 
measures. Until our study was performed, it was completely unknown how 
vascular surgery affects arterial stiffness and whether its change is related to 
cardiovascular events. Based on our study (Paper I), vascular surgery has a positive 
impact on decreasing arterial stiffness parameters measured approximately 24 
hours after surgery. However, the decline in arterial stiffness 24 hours after 
surgery reflects not only the effects of vascular manipulation, but also the impact 
of anaesthesia and perioperative medication, as well as the impact of acute stress 
from the trauma caused by surgery itself. Yet the results from the Paper I, indi-
cating that surgery and anaesthesia with medication may affect arterial stiffness 
and haemodynamics, have some clinical relevance. Perioperative monitoring of 
arterial stiffness, an independent predictor of cardiovascular events and mortality, 
may facilitate guided treatment and prevention of the cardiovascular risks of 
patients undergoing vascular surgery. Perioperative increase of central haemo-
dynamics and arterial stiffness may result in elevated cardiac afterload and 
reduced coronary perfusion, which presumably leads to a greater risk of 
cardiovascular events (myocardial infarction, heart failure, stroke, etc.). 
Perioperative leakage of cardiac enzymes may be associated with cardio-
vascular events as it has been linked to increased risk for 30-day mortality (Redfern 
et al. 2011; Vascular Events In Noncardiac Surgery Patients Cohort Evaluation 
(VISION) Study Investigators et al. 2012). Nevertheless, there was no correlation 
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between leakage of cardiac enzymes and change in the parameters of arterial 
stiffness in our study (Paper II). Although our study may have been too small to 
evaluate correlations between clinical outcomes and changes in the parameters of 
arterial stiffness, it is still possible to draw some conclusions. Notably, changes 
in the parameters of arterial stiffness are not associated with cardiac damage 
(Paper II). However, there was positive correlation between baseline AIx and 
increase of hs-TnT in the RIPC group, which indicates that the protective effect 
of RIPC is more pronounced in patients with lower baseline AIx (Paper II). This 
finding may imply a stronger effect of RIPC in young participants, as younger 
people principally have better arterial compliance and hence lower AIx. Although 
in our study there were no correlations between leakage of cardiac enzymes and 
age, the weight of person’s vascular age on the effect of RIPC may be more 
substantial than that of his/her biological age. 
In longer term, the material and location of vascular graft may have a crucial 
impact on arterial stiffness, in particular, on PWV. Finally, the long-term effect 
of vascular surgery on arterial stiffness may be completely different from the 
immediate effect, which needs additional studies.  
 
 
6.2. Impact of RIPC in cardioprotection:  
from clinically non-substantial changes  
to clinically relevant effects 
Cardioprotective effects of ischaemic conditioning is the most widely studied 
(Annachhatre and Annachhatre 2019) issue in this field. There are multiple 
animal studies, which have demonstrated that RIPC reduces the size of myocardial 
infarction(Gho et al. 1996; Tang et al. 1999; Schoemaker and van Heijningen 
2000; Liem et al. 2002; Weinbrenner et al. 2002; Konstantinov et al. 2005; 
Wolfrum et al. 2005; Zhang et al. 2006; Dong et al. 2018; Lieder et al. 2018; 
Bunte et al. 2019). These data, when translated to humans, may help to maintain 
physical capability and also quality of life. Unfortunately, human studies showing 
a positive effect of RIPC on cardiac enzymes or size of myocardial infarction, 
with simultaneous assessment of quality of life, are missing. A large study reported 
no clinical effect (including quality of life) in patients undergoing cardiac surgery 
(Hausenloy et al. 2015). However, the above trial found no effect of RIPC on 
enzymatic cardiac damage. There are several “proof of concept” studies on 
humans that have obtained positive results (Hausenloy et al. 2007; Venugopal et al. 
2009; Wang et al. 2019b). Many studies on RIPC, including our study, have used 
cardiospecific biomarkers as primary or secondary outcome. In recent years, 
more studies have concentrated on the clinical benefit of RIPC (Hausenloy et al. 
2015; Meybohm et al. 2015). Studies focusing on clinical outcomes have mostly 
obtained neutral results (Hausenloy et al. 2015; Meybohm et al. 2015). Similarly, 
a number of meta-analyses showed no effect of RIPC on all-cause mortality, 
myocardial infarction, renal failure, stroke or length of ICU or hospital stay in 
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patients undergoing cardiovascular surgery (Haji Mohd Yasin et al. 2014; 
Remote Preconditioning Trialists’ Group et al. 2014; Pierce et al. 2017). Also, 
one meta-analysis has presented positive effects on cardiospecific biomarkers, but 
not on clinical outcomes (Xie et al. 2018). Despite the fact that according to some 
meta-analyses, RIPC reduces the incidence of myocardial infarction (Pei et al. 
2014; Wang et al. 2017a), definite final conclusions about its clinical benefit 
regarding cardioprotection cannot be drawn.  
Postoperative leakage has also some clinical value in predicting vascular and 
non-vascular 30-day mortality. It has been reported that the higher is post-
operative leakage of TnT, the higher is mortality (Redfern et al. 2011; Vascular 
Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study 
Investigators et al. 2012). Likewise, micro-leakage of TnT predicts mortality and 
subsequent myocardial infarction in patients undergoing elective PCI (Milani et 
al. 2009). Also, postoperative elevation of BNP or NT-proBNP has been 
associated with increased risk for mortality, myocardial infarction and cardiac 
failure (Rodseth et al. 2013). Based on the above findings, we can assume that 
the effect of RIPC in reducing cardiospecific biomarkers may have some clinical 
value. Still, there is no proof that reducing perioperative or -procedural leakage 
of cardiospecific biomarkers leads to better long-term outcomes. Leakage of 
cardiac biomarkers may merely have a predictive value without affecting the 
clinical result.  
In our study (Paper II), RIPC displayed its cardioprotective effects by reducing 
the leakage of hs-TnT and NT-proBNP in association with vascular surgery. 
However, our study was probably too small to detect any significant differences in 
clinical outcomes in the acute postoperative period. Still, as the increase of NT-
proBNP was significantly higher in the sham group, RIPC might have an effect 
in lowering the rate of perioperative acute heart failure. This is supported by the 
fact that two cases of acute heart failure occurred in the sham group but none in 
the RIPC group (Paper II). Still, a larger study is needed to evaluate the relevance 
of this observation, as well as the overall effect of RIPC on the cardiovascular 
system. A negative correlation between change in hs-TnT and change in eGFR 
occurred in both groups while the correlation was stronger in the RIPC group 
(Paper II). Therefore, the increase of hs-TnT may have been more likely 
connected with the decrease in kidney function in the RIPC group than in the 
sham group. 
According to Cochrane systematic review RIPC reduces leakage of TnT but 
does not have any impact on clinical outcomes assessed as the composite endpoint 
(including all-cause mortality, myocardial infarction, or stroke) in cardiac surgery 
(Benstoem et al. 2018). Negative results from studies may be explained with 
presence of important confounders (e.g propofol anaesthesia) and the hetero-
geneous nature of patient groups. Furthermore, the heterogeneity of individual 
studies is a major drawback in meta-analysis. In addition, the majority of studies 
assessing cardioprotection have been conducted on patients undergoing cardiac 
surgery or elective PCI, while only some studies have focused on patients with 
acute diseases. For example, remote ischaemic conditoning has been found to 
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reduce leakage of cardiospecific biomarkers and to preserve left ventricular 
contractility (Cao et al. 2018), as well as to reduce cardiac mortality and hospital-
ization for heart failure (Gaspar et al. 2018) in patients with STEMI. This suggests 
that the effect of RIPC may be more pronounced in specific circumstances, e.g. 
in type I acute myocardial infarction. Moreover, animal studies are usually per-
formed in the case of acute occlusion of coronary artery and many of them have 
shown that IPC reduces infarction size (Gho et al. 1996; Tang et al. 1999; 
Schoemaker and van Heijningen 2000; Liem et al. 2002; Weinbrenner et al. 2002; 
Konstantinov et al. 2005; Wolfrum et al. 2005; Zhang et al. 2006; Dong et al. 
2018; Lieder et al. 2018; Bunte et al. 2019). However, additional, preferably 
homogeneous, large studies are needed to verify these assumptions. It should be 
clarified which patients would experience a strong protective effect of RIPC. The 
results of Paper II suggest that the effect of RIPC is stronger in those vascular 
surgery patients who are treated with statins, but also in patients with lower aug-
mentation index, and hence with better arterial compliance, and in male patients. 
There is also similar proof from previous studies (El Desoky et al. 2016; Cho et 
al. 2019).  
In conclusion, the clinical benefit of RIPC regarding heart is yet to be estab-
lished. Future research should be more concentrated on patient-related outcomes 
as the protective concept of ischaemic conditioning has been quite well proved. 
 
 
6.3. Role of RIPC in nephroprotection:  
a strategy to reduce acute kidney injury  
in lower limb revascularisation surgery? 
AKI is a possible complication of many acute diseases and medical procedures. 
Vascular surgery is high-risk surgery in which postoperative AKI has been found 
to occur in 12.7–49% of patients (Adalbert et al. 2013; Huber et al. 2016). In 
revascularisation, serious I/R injury and clinically insignificant rhabdomyolysis 
are inevitable and increase the risk for kidney injury. Perioperative AKI is related 
to higher cardiovascular morbidity, mortality, risk for chronic kidney injury and 
longer hospitalisation. Moreover, elevation of creatinine level even below the 
AKI criteria has been linked to adverse outcome both in cardiac (Lassnigg et al. 
2008) and non-cardiac surgery (Kork et al. 2015). Nonetheless, AKI has still 
remained an underdiagnosed and undertreated problem and effective strategies to 
avoid or reduce AKI are lacking. In this light, RIPC has emerged as a possible 
strategy to reduce AKI. A relatively large study whose primary outcome was 
postoperative renal function showed that RIPC reduces the rate of AKI within the 
first 72 h after surgery, the need for kidney replacement therapy and the intensive 
care unit stay in patients requiring cardiac surgery (Zarbock et al. 2015). Addi-
tionally, long-term kidney protection and improved renal recovery in the case of 
AKI were reported in a follow-up analysis (Zarbock et al. 2017). Two large 
studies, RIPHeart (Meybohm et al. 2015) and ERICCA (Hausenloy et al. 2015), 
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where postoperative kidney function was a secondary outcome and propofol 
anaesthesia was used, no benefit of RIPC on kidney function was reported in 
patients undergoing elective coronary artery bypass grafting surgery with or 
without valve surgery. However, in a meta-analysis, RIPC reduced the incidence 
of AKI in studies where propofol was not administrated (Pierce et al. 2017). 
Hence, it seems that propofol may be an important confounder to nephroprotection 
by RIPC. In our study, RIPC showed a nephroprotective effect by lowering kidney 
injury biomarkers in a subgroup analysis of patients undergoing lower limb 
revascularisation surgery (Paper III). However, in the whole study group, no 
significant effect of RIPC was observed however. This may have been due to the 
administration of propofol, as carotid endarterectomy and abdominal aortic 
aneurysm repair were both performed under general anaesthesia, propofol being 
the most common anaesthetic. Also, propofol was administered to 25% of 
patients undergoing lower limb revascularisation surgery in the RIPC group. 
Because of this, the true effect of RIPC might have been underestimated. It was 
not possible to accurately evaluate the presence of AKI according to the KDIGO’s 
criteria (Khwaja 2012) that require AKI to be diagnosed on the basis of creatinine 
and urine output changes within 7 days. Our trial, however, lasted only 24 hours 
after surgery (Paper III). Still, in a subgroup analysis of patients undergoing lower 
limb revascularisation surgery AKI was present in 4 patients (14%) in the sham 
group and in 1 patient (4%) in the RIPC group during the follow-up period, yet 
the difference was not statistically significant (Paper III). However, it is likely 
that more patients developed AKI in the post-trial period. Moreover, we excluded 
patients with eGFR <30 mL/min/1.73m2, who were at greater risk for AKI. In the 
earlier studies, one of the exclusion criteria was also eGFR <30 mL/min/1.73m2 
(Hausenloy et al. 2015; Meybohm et al. 2015). At the same time, studies assessing 
the nephroprotective effect of RIPC in patients with more severe chronic kidney 
disease are missing. 
Taken together, RIPC might be a clinically valuable option for vascular surgery 
patients to reduce the incidence of AKI, especially as well-established procedures 
for decreasing perioperative AKI are lacking. Reduction in perioperative AKI 
could shorten hospital stay and improve prognosis. Furthermore, RIPC is a low-
cost procedure and, according to our findings, it is easily applicable and well 
tolerated by patients, facilitating its usage in clinical practice. 
 
 
6.4. Shifts in acylcarnitines’ metabolism after RIPC:  
a novel insight into potential mechanisms/targets of RIPC?  
Unfortunately, no studies have evaluated the effect of RIPC on carnitine (C0) 
level and on the profile of all acylcarnitines (C2-C18). Still, relevant conclusions 
can be drawn based on our study IV). Paper IV reports the positive effect of RIPC 
in lowering the levels of several ACs in patients undergoing vascular surgery, 
which is also an evidence of its effect on the ACs’ profile in plasma. According 
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to previous studies, decrease of the levels of ACs can be associated with preserved 
mitochondrial function (Bjørndal et al. 2018). The knowledge of the ACs profile 
may facilitate assessment of patients’ general metabolic milieu, mitochondrial 
functioning and prognosis. As ACs have a different origin in plasma, plasma ACs 
does not directly reflect whole-body acylcarnitine metabolism (Schooneman et 
al. 2015), but it allows to make some conclusions about its metabolism in certain 
organs. Plasma SCASs have been found to be released from liver (Schooneman 
et al. 2015), while plasma MCACs are released from skeletal muscles and liver 
(Xu et al. 2016) and LCACs, from heart (Makrecka-Kuka et al. 2017). It should 
be noted that the hepatoprotective effect of RIPC has been reported previously 
(Kanoria et al. 2017; Wu et al. 2019). In our study, there occurred an increase of 
some SCACs levels in the sham group and no increase of ACs in the RIPC group 
(Paper IV).  
Evidently, the stress caused by surgery enhances the catabolism of BCCA in 
liver in order to produce additional metabolic energy, which is accompanied by 
an increase of plasma SCACs. RIPC has been found to intensify hepatic oxy-
genation and hepatic microcirculation via the activation of eNOS (Abu-Amara et 
al. 2011), as well as to increase the expression of protector proteins including heme 
oxygenase 1 (Cornide-Petronio et al. 2019), which preserves mitochondrial func-
tionality. Hence, by using RIPC, the produced SCACs can be spent more effi-
ciently. Considering the above findings, it can be supposed that RIPC might have 
a protective effect on liver.  
In addition, we currently found a significant difference in the levels of C3-OH 
between the RIPC and the sham group (Paper IV). Surgery increases the demand 
for metabolic energy and may also cause elevated level of ketone bodies leading 
to production of C3-OH. The above significant difference could be explained by 
a more effective elimination of this SCAC or by a lesser need for ketone bodies 
in case RIPC is applied. Moreover, Paper IV describes positive correlations 
between decrease of cardiac biomarkers (NT-proBNP and hsTnT) and decrease 
of several ACs in the RIPC group. This allows to suggest cardioprotective effects 
based on shifts in the levels of ACs. However, further studies are needed to 
corroborate these assumptions. 
Summing up, according to our study, it can be concluded that RIPC has an 
effect on the levels of ACs and can therefore have protective effects on mito-
chondria in patients undergoing vascular surgery. Further research is needed to 
make more definite conclusions about the effect of RIPC on the levels of ACs. 
 
 
6.5. Possible causes of contradictory results  
from human studies 
While animal studies have consistently reported positive effects of RIPC, studies 
on humans have shown more contradictory results. Animal studies are easier to 
perform in a uniform manner while human studies involve many confounders 
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which are difficult to avoid; also, human study populations tend to be more hetero-
geneous. The present study was faced with similar issues. Long-term research of 
the effects of ischaemic conditioning with varying results allows to suggest that 
ischaemic conditioning has beneficial effects only under certain conditions and 
in certain patients. Various factors have been found to mitigate or abolish the effect 
of ischaemic conditioning (e.g. propofol, gender, age, diabetes etc.) (Penna et al. 
2009; Oosterlinck et al. 2013; Pierce et al. 2017; Zhou et al. 2017; Behmenburg 
et al. 2018; Heinen et al. 2018; Moretti et al. 2018; Wider et al. 2018; Bunte et al. 
2019). Also, as the effect of RIPC may vary in high and low risk patients, this 
may explain in part the contradictory results. All these confounders may have 
played a certain role in the results of our study: propofol usage, inclusion of diabetic 
patients and absence of limitations regarding gender and age. Most human studies 
have failed to avoid these possible confounders, first and foremost usage of pro-
pofol for anaesthesia (Hausenloy et al. 2015; Meybohm et al. 2015). Yet as pro-
pofol is a standard drug for sedation worldwide, it would be complicated to apply 
propofol-free sedation in clinical practise. Hopefully more homogenous or larger 
studies will be conducted in future. This would help to clarify the true effect of 
RIPC, as well as the issue of suitability of patients to be selected for RIPC. 
At the same time, there is a possible cause of negative results which could be 
easier to modified. Only a few papers have evaluated different protocols of RIPC 
(Pei et al. 2014; Johnsen et al. 2016). Usually, protocols consisting of 2–8 cycles 
of ischaemia lasting 2–10 minutes have been applied to one or two limbs (Johnsen 
et al. 2016). However, an early RIPC study reported positive results with only 
one 15-minute cycle of RIPC (Gho et al. 1996). The delayed effect of RIPC (Kim 
et al. 2017) is relatively less studied than the acute effect. The delayed phase and 
the acute phase of RIPC have been compared with contradictory results (Dow et 
al. 2012; Rohailla et al. 2014; Varga et al. 2019). Unfortunately, not all protocols 
of RIPC may be equally favourable. The timing of conditioning and the protocol 
of the current study may have had an impact on the results. Once the most bene-
ficial protocol is developed, it will be possible to evaluate the true effect of RIPC.  
 
 
6.6. Limitations 
There are several limitations associated with this series of studies. First, the main 
limitation is the small size of the study group, which made assessment of the 
clinical outcomes very difficult. Power calculation was based on AIx@75 and an 
effect size of 5 units (%) was chosen as possible meaningful change and only 
post-hoc power calculations were carried out basis of the other outcomes. Un-
fortunately, there is no solid proof or recommendations regarding what change in 
AIx@75 is relevant. It may be that a smaller change than 5 units (%) of AIx@75 
is clinically important and, to reach statistical significance, a larger study group 
would have been necessary. Also, power calculation did not take account the 
possible confounders, that were present in this study, which can impact the 
results. Second, negative results of primary outcomes may lessen the importance 
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of secondary outcomes. Yet as the secondary outcomes may not have been clini-
cally or pathophysiologically connected with primary outcomes, the positive 
results of the secondary outcomes may be relevant and the effect of RIPC on the 
biomarkers’ level may have some clinical value as discussed above.  
Third, there are multiple possible confounders in this study. The main con-
founder to the effect of RIPC is the use of propofol anaesthesia (Behmenburg et 
al. 2017; Bunte et al. 2019), which probably weakened the effect of RIPC. Also, 
the true effect of RIPC may have been attenuated by recruiting diabetic patients 
as diabetes has also been described as an important confounder to its effect (Jensen 
et al. 2013; Oosterlinck et al. 2013). Moreover, there was considerable hetero-
geneity among the study population, with one group of patients, having occlusive 
arterial disease and the others having aneurysmal disease. This may have led to 
different impacts due to clamping and reperfusion in the recruited patients. In the 
case of lower limb occlusive disease, the effect of clamping and reperfusion is 
weaker than it is during aortic aneurysm repair surgery where arteries are unob-
structed. So a more systemic effect can be achieved in the case of aortic aneurysm. 
Also, patients with claudication are believed to have chronic ischaemic con-
ditioning, which may have reduced the effect of RIPC intervention. Additionally, 
the involved surgeries were different in other aspects, such as duration and pre-
paration for anaesthesia and surgery. This resulted in different periods from 
intervention to I/R, as the intervention was performed after the patient had arrived 
in the operating theatre. It is possible that the patient experienced a different effect 
of RIPC namely due to these temporal variations. Still, as the “first window” of 
the effect of RIPC is known to last approximately a few hours, one can not expect 
significant differences here. Also, clamping time and location varied among 
surgeries and I/R injuries and so the patients may have experienced different 
severities of ischaemia-reperfusion injury. In addition, the material of vascular 
graft may also have an impact, in particular, on pulse wave travelling. Yet, it is 
not clear how large the impact of a few-dozens-centimetre graft is among other 
contributing factors. Moreover, it is even unknown how different grafts affect the 
pulse wave. Finally, the peripheral graft type could potentially also influence the 
parameters of arterial stiffness. 
 
 
6.7. Concluding remarks and future perspectives 
RIPC is a promising method to be used in clinical practise in order to ameliorate 
clinical outcome. The present thesis provides proof that RIPC reduces cardiac 
and kidney damage in vascular surgery, and that its effects are achieved through 
changes in the metabolism of ACs. Considering perspectives, long-term follow-
up of the same cohort could describe the effect of RIPC on total mortality, cardio-
vascular morbidity and mortality, and major adverse limb events. Analysis of 
changes in other metabolites, in addition to ACs, could offer knowledge about 
the exact mechanisms of RIPC. A new larger study that presupposes international 
collaboration could enlighten the clinical benefits of RIPC and would specify who 
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can benefit the most from RIPC. Additionally, it should be clarified if it is 
possible to enhance the effect of RIPC by using some medications, supplements 
or other strategies. 
 
 
6.8. Conclusions 
1. There were no significant differences between the RIPC group and the sham 
group in terms of the postoperative changes in augmentation indices, pulse 
wave velocity and indices of arterial elasticity. Hence, RIPC had no effect on 
arterial stiffness in patients undergoing vascular surgery. Significant post-
operative improvements in the augmentation indices and small artery elasticity 
within both groups indicate that the surgical procedure itself may acutely 
ameliorate arterial stiffness, while these changes may be related to the systemic 
stress response to surgery, anaesthesia and perioperative medications. 
2. There was significantly higher leakage of high hs-TnT and NT-proBNP in the 
sham group compared to the RIPC group. Accordingly, RIPC offers cardio-
protection by significant reduction in leakage of cardiac biomarkers hs-TnT 
and NT-proBNP in patients undergoing vascular surgery. Additionally, since 
negative correlation between increase of cardiac biomarkers and pretreatment 
with statins and positive correlations of increase of cardiac biomarkers with 
gender (male<female) and baseline augmentation index were observed in the 
RIPC group, it can be concluded that the effect of RIPC may be stronger in 
patients, who receive statins, particularly in those with lower arterial stiffness, 
and in males. RIPC may thus serve as a protective measure against peri-
operative cardiac damage. 
3. In patients undergoing surgical revascularisation of lower limb, serum 
creatinine, cystatin C and beta-2 microglobulin increased and eGFR decreased 
across all time points significantly more in the sham group than in the RIPC 
group. Hence, RIPC reduces leakage of the biomarkers indicative of kidney 
injury and renal function in these patients and could be a protective measure 
against acute kidney injury. 
4. The pattern of acylcarnitines differed between the RIPC group and the sham 
group, yet there was no statistically significant difference in the changes of 
most acylcarnitines. RIPC, but not sham, application decreased the levels of 
certain short and medium chain acylcarnitines in the RIPC group, which was 
not noted in the sham group. There was a statistically significant difference 
between the groups regarding changes in C3-OH: a decrease in the RIPC 
group and an increase in the sham group. Thus, RIPC has an effect on the 
levels of ACs and may therefore have protective effects on mitochondria in 
vascular surgery patients.  
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SUMMARY IN ESTONIAN 
Kaugisheemilise eelkohastamise mõju elundikahjustusele ja 
atsüülkarnitiinide ainevahetusele veresoontekirurgias 
Veresoontekirurgia on kõrge riskiga kirurgia, kuna patsiendid on süsteemsest 
ateroskleroosist tulenevalt mitmete kaasuvate haigustega. See suurendab haigetel 
operatsiooniaegsete ja -järgsete tüsistuste esinemise tõenäosust. Veresoonte-
kirurgias olulist rolli mängiva isheemia-reperfusioonikahjustuse vähendamise 
võimalusena on viimase 30 aasta jooksul uuritud isheemilist eelkohastamist. 
Viimase erivorm, kaugisheemiline eelkohastamine (KIE), seisneb lühiajalistes 
eemal paikneva koe (nt. ülajäseme) isheemia episoodide tekitamises, mille ees-
märgiks on kaitse loomine sihtelundile. Enim uuritud sihtelundid on süda ja 
neerud, kuid põhimõtteliselt võib selleks olla ükskõik milline isheemiatundlik 
kude. Mitmetes senistes uuringutes on ilmnenud KIE kaitsev toime südame- ja 
neerukahjustusele, kuid on leitud ka KIE mittetoimimist. Enamik KIE uuringuid 
on läbi viidud patsientidel, kellel on teostatud kas lahtine südameoperatsioon või 
perkutaanne pärgarterite angioplastika. Veresoontekirurgias on KIE efekti vähem 
uuritud. Kuigi on tuvastatud mitmeid KIE efektis osalevaid tegureid, siis täpsed 
KIE toimemehhanismid ei ole teada. Avastatud on ka KIE toimet vähendavaid 
mõjureid, sealhulgas näiteks vanus, suhkruhaigus ja anesteetikum propofool. 
Käesolev doktoritöö kirjeldab KIE mõju arterite jäikusele, südame- ja neeru-
kahjustusele ning atsüülkarnitiinide ainevahetusele veresoontekirurgia patisenti-
del. Juhuslikustatud topeltpimendatud kontrollitud kliinilisse uuringusse kaasati 
98 uuritavat. Peale väljalangemist jäi KIE gruppi 45 ja kontrollgruppi (sham ehk 
imitatsioon) 48 patsienti. Menetluseks oli operatsioonieelselt vererõhu mansetiga 
tehtud 4 tsüklit 5-minutilist ülajäseme isheemiat (mansetis rõhk vähemalt 
200 mmHg) 5-minutiliste reperfusiooni pausidega ning kontrollrühmas rakendati 
ülajäsemele isheemia asemel mansetis venoosset rõhku (10–20 mmHg). 
Arterite jäikusele KIE-l mõju ei leitud, küll aga paranesid operatsioonijärgselt 
mõlemas uuringugrupis märgatavalt arterite jäikuse parameetrid. Need akuutsed 
muutused arterite jäikuses on tingitud nii operatsioonitraumast, anesteesiast kui 
ka manustatud ravimitest. Uuringu tulemusena esines oluline gruppide vaheline 
erinevus postoperatiivselt südamekahjustuse markerite (kõrgtundlik troponiin T 
ja NT-proBNP) muutustes – KIE grupis oli markerite tõus väiksem. Lisaks oli 
KIE grupis negatiivne seos südamekahjustuse markerite taseme tõusu ja eelneva 
statiinravi vahel ning positiivne seos südamekahjustuse marketite tõusu ja soo 
(mees<naine) ning algtaseme augmentatsiooni indeksi vahel. Sellest võib järel-
dada, et KIE vähendab perioperatiivset südamekahjustust veresoontekirurgilistel 
operatsioonidel ning KIE toime on tugevam statiinravil ning meessoost ja 
elastsemate arteritega haigetel. Täiendavalt oli KIE grupis väiksem neerukahjus-
tuse markerite tõus alajäseme revaskulariseerival operatsioonil käinud pat-
sientidel, mis näitab KIE neerukahjustustust vähendavat toimet. Lisaks oli KIE-l 
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positiivne toime atsüülkarnitiinide tasemele, mis viitab mitokondrite kaitsele ja 
avardab teadmisi ka KIE toimemehhanismidest ja sihtmärkidest.  
Kokkuvõtvalt on KIE potentsiaalseks menetluseks neeru- ja südamekahjus-
tuse vähendamiseks veresoontekirurgias. KIE toime on seotud mitme kliinilise 
teguriga ja ka positiivsete muutustega atsüülkarnitiinide ainevahetuses. Kliinilise 
kasutuse tõhususe täpsustamiseks on vajalikud suuremad ja homogeensema 
uuringugrupiga uuringud. 
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